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Some experts say we are moving back to the pre-antibiotic era. 
No. 
This will be a post-antibiotic era. In terms of new replacement antibiotics, the pipeline is 
virtually dry. A post-antibiotic era means, in effect, an end to modern medicine as we know it. 
Things as common as strep throat or a child's scratched knee could once again kill. 
Margaret Chan, WHO Director (1947- )  
 
If you cannot measure it, 
you cannot improve it. 
Lord Kelvin, scientist (1824-1907) 
 
Progress is made by lazy men 
looking for easier ways to do things. 
Robert A. Henlein, sci-fi author (1907-1988) 
 
Give me six hours to chop down a tree  
and I will spend the first four sharpening the axe.  
Abraham Lincoln, American president (1809-1865) 
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1. General background 
1.1. Antibiotics and modern medicine 
No class of drug can compete with antibiotic agents in terms of a definite cure of disease and, 
above all, the extent of mortality reduction these drugs have contributed over the last 70 years. 
Nonetheless, infectious diseases even today kill and disable on a large scale in developing 
countries and regions with little economic resources. A fortunate minority of the world 
population has almost unlimited access to diagnostic and therapeutic resources, including 
antibiotic supplies, which is taken for granted. The inhabitants of the industrialized societies have 
limited understanding of the tremendous impact that infectious diseases made on the lives of 
their ancestors only a few decades ago.  
With the historical backdrop in mind, there is no doubt that the control of infectious diseases by 
use of antibiotics is one of the most important achievements in the history of medicine. To keep 
this precious asset intact, the prescribing of antibiotics should be an exclusive domain of 
physicians, which indeed is the case in many industrialized countries. Unfortunately, these basic 
conditions are non-existing in large parts of the world. Thus, lack of money or non-availability 
of drugs are the only factors that constrain an uncontrolled and potential limitless use.  
1.2. An antibiotic paradox 
Soon after the discovery of antibiotics, bacteria with resistance to the drugs emerged.  
Alexander Fleming, the discoverer of 
penicillin, made a prophetic statement in 1945 
when he was interviewed in the New York 
Times about the future of the miracle drug:  
“… the public will demand [penicillin]…then 
will begin an era…of abuses. The microbes are 
educated to resist penicillin and a host of 
penicillin-fast organisms is bred out which can 





be passed to other individuals and perhaps from there to others until they reach someone who 
gets a septicemia or a pneumonia which penicillin cannot save. In such a case the thoughtless 
person playing with penicillin treatment is morally responsible for the death of the man who 
finally succumbs to infection with the penicillin-resistant organism. – I hope the evil will be 
averted.” 1 
Unfortunately, the evil has not been averted.  
The increase in antibiotic resistance is proportional to the use of antibiotics. 2-5 Although this has 
long been a common knowledge, antibiotic use has increased tremendously over the last decades. 
This is because of the immediate benefits that emerged for a wide range of medical specialties 
with the use of antibiotics. Combined with the simultaneous advances in anaesthesiology and 
antisepsis it became possible to cure patients on a scale never before imagined. The drawback 
has been that modern medicine also causes an increasing number of immunocompromised 
patients and complications, for example in relation to advanced surgery. This, in turn, 
necessitates even more use of antibiotics and the demand for more sophisticated antibiotics 
arises. This spiral of events – which may seem as a paradox, but is in fact a consequence of 
evolutionary processes in nature – has led to a global epidemic of antibiotic resistance. Already 
for many years, this unfortunate development has been perceived as one of the most serious 
threats to human health. 6,7  
1.3. The antibiotic resistance challenge 
At least three elements of antibiotic use make it difficult to reverse the global escalation of 
antibiotic resistance.  
First, there is a contradiction between the need to treat seriously infected patients effectively and 
the need to restrict antibiotic use to prevent antimicrobial resistance development. 8 This 
dilemma is ubiquitous in the physician-patient setting, be it in the intensive ward of a modern 
hospital or in a remote village in Africa. In recent years the ethical question has been raised, at 
least in industrialized settings, if today’s patients may be requested to refrain from special 
antibiotics, or even being actively withheld antibiotic treatment altogether for mild and moderate 
infections, in order to preserve these life-saving drugs for future generations. 9    





Second, new antibiotics are urgently needed but their development is hampered by generally 
modest income prospects for the pharmaceutical industry. 10-14 Almost no new substances, only 
variations of the old, have been developed in recent decades. The development of new drugs is 
seriously restricted by a lack of investments, partly due to a concern shared by most companies 
that resistance will render a new antibiotic – developed at a high cost – ineffective after a 
relatively short time.   
The final and maybe most easily accessible element of the resistance problem deals with 
counteracting an overuse and misuse of antibiotics, caused by physician’s lack of knowledge and 
ignorance of the ecological side effects 15-17 and the influence from profit-makers. 18 
Norway and the other 
Scandinavian countries (and the 
Netherlands) still have a relatively 
low level of antibiotic resistance 
among pathogenic bacteria as 
compared with most other 
countries 19 (Figure 1.1).  
There are several reasons for this; 
not all of them are obvious and 
well identified. Cultural and socio-
economic factors play a role 20 and 
the extent of self-medication with 
antibiotics also differs widely 
between countries. 21,22  
To some degree, one is left to 
hypothesize about the reasons for the county differences. One very probable explanation is the 
fact that there are fewer antibiotic substances registered in countries with a lower level of 
resistance than what is the case in countries with extensive resistance. A survey in 2001 of 139 
European hospitals concluded that the number of registered antibiotics had an impact on 
antibiotic consumption. With increasing number of available antibiotics, higher consumption 
figures could be observed (Spearman rank correlation 0.40, P < 0.01). 23 The numbers of 
registered antibiotics in various countries are surprisingly difficult to obtain but in 2010 the 
Figure 1.1 ECDC 2012: Methicillin-resistant 
Staphylococcus aureus (MRSA) in Europe, 2011.  
(From ECDC 2012 Resistance Report, Europe) 





international ATC J01 (Antibacterials for systemic use) registry listed 229 antibiotic substances 
or their combinations (e.g. J01CA04 benzylpenicillin), classified into 33 chemical groups (e.g. 
J01CE, penicillinase-sensitive penicillins) and furthermore into 10 pharmacological subgroups 
(e.g. J01C, penicillins). 24 The corresponding numbers for Norway were 44, 22 and 8.  
Moreover, a greater availability of 
antibiotics may also be related to a 
larger density of pharmaceutical 
services. A review article from 2001 
25 showed a large variation in the 
number of inhabitants per pharmacy 
between selected European 
countries in 1996 (Figure 1.2). The 
ranking order of countries by use of 
this measure is largely a reverse 
order of the antimicrobial resistance 
ranking in Europe today, almost 20 
years later.    
A favourable resistance situation – 
like it presently is in Scandinavia 
countries – should be an added 
incentive to monitor the situation 
very closely and to respond 
appropriately. There is ample evidence that development of antibiotic resistance is easier to 
prevent or delay in a situation with low-grade resistance than it is to attack and reduce after it 
has reached a certain level. 26  
Several mechanisms and factors are contributing to the development of antimicrobial resistance. 
While there is no dispute concerning the relationship between antibiotic use and antibiotic 
resistance in microorganisms, a simple “drug-bug” connection is rarely straightforward. 27 For 
instance, it has been shown that the penicillin-resistance in pneumococci is less promoted by the 
use of beta-lactam antibiotics than by the use of macrolides. 28 The drivers for methicillin-
resistance in Staphylococcus aureus (MRSA) are to a larger extent quinolones, glycopeptides 
Figure 1.2  Number of inhabitants per pharmacy in 
Europe, 1996





and cephalosporins than are penicillins. 29 For emergence and persistence of vancomycin-
resistant enterococci (VRE) in hospitals, extensive use of extended-spectrum cephalosporins, 
quinolones and antibiotics against anaerobic infections probably have a more significant impact 
than a high-level use of vancomycin. 30 
1.4. Antibiotic resistance in hospitals 
Antibiotic use in hospitals account roughly for only 5-15% of total use in the community, and 
this proportion is more or less the same, and has been relatively stable, all over the developed 
world. Although accounting only for only a fraction of total antibiotic use, hospitals are beyond 
doubt the most important sources for antibiotic resistance development. Hospital environments 
are also prone to establish a high endemicity for opportunistic and resistant microorganisms.  
In a joint SHEA/IDSA*  guideline for antibiotic resistance prevention, Shales et al referred to 
early insights about antibiotic resistance presented in a seminal work by McGowan 31 and 
summarized seven main mechanisms for the appearance or spread of resistance in hospital 
organisms: 32  
x Greater severity of illness of hospitalized patients.  
x More severely immunocompromised patients. 
x Newer devices and procedures in use. 
x  Increased introduction of resistant organisms from the community. 
x  Ineffective infection control and isolation practices and compliance. 
x  Increased empirical polymicrobial antimicrobial therapy. 
x High antimicrobial usage for geographical area per unit time. 
More risk factors are present in hospitals than in the community and the interactions between 
them are complex. Apart from the larger volumes of advanced antibiotics being used, the risk of 
resistance development is imminent because of the particular environments, with multiple sick 
individuals living in contained areas.  
* SHEA: The Society for Healthcare Epidemiology of America, IDSA: Infectious Diseases Society of America 





1.5. Resistance surveillance 
Resistance surveillance, no matter how accurate and sophisticated, will be of little use without 
further analyses and interpretations based on knowledge of resistance mechanisms and the 
interactions between microorganisms. Monitoring of antibiotic resistance is needed to be able to 
reverse or at least delay the escalation of the problem. On a national scale, a routine monitoring 
is necessary because significant national resistance trends may have an impact on general 
recommendations for antibiotic use. In addition, it is important to identify hospitals with outlier 
resistance values e.g. in order to adjust recommendations for antibiotic therapy and to detect 
outbreaks. Finally, international surveillance networks have been established for which it is 
pivotal to contribute national data. 19,33,34 
Resistance monitoring on the local hospital level should be performed for several reasons: 
x Deviations from national resistance rates may be observed and call for local 
adjustments of recommendations for antibiotic use. 
x Local resistance statistics may be used for education purposes to change physician’s 
prescription habits. 
x Surveillance may facilitate the detection of outbreaks with multiresistant 
microorganisms. 
1.6. The antibiotic stewardship program 
Many determinants for the rational use of antibiotics are similar whether the antibiotics are 
prescribed in hospitals or in the community. Nonetheless, physicians working in hospitals 
encounter different, and mostly more complex, clinical scenarios than those dealt with by 
colleagues working in the community. In recognition of this fact, the concept of an “antibiotic 
stewardship program” has been specifically developed for health care institutions.  
A concise definition has been proposed by Tamma and Cosgrove 35 who state that antimicrobial 
stewardship “- refers to a program or series of interventions to monitor and direct antimicrobial 
use at a health care institution, thus providing a standard, evidence-based approach to judicious 
antimicrobial use.” Extensive American guidelines for antimicrobial stewardship in hospitals 





were endorsed in 2007. 36  
The choice of measures should be based on the evidence of the measures’ effect and the 
probability of success in the local hospital setting. Cost considerations are also important, in 
particular as an argument to allocate sufficient resources for the program.  
In what was called the “holy trinity” of resistant development and dissemination (  Figure 1.3), 
a recent review of modern antimicrobial stewardship describes the interplay between infection 
control factors, environmental influencers and the exposure to antibiotics. 37 
 
 
In recognition of the fact that antibiotic resistance has multiple causes and no single action or 
measure can eliminate the problem, the concept of “intervention bundles” has been introduced. 
The utility of implementing a set of measures, tailored to local needs, have since been reported 
in several studies. 38-40 The bundles may be seen as sets of locally adjusted and practically 
designed procedures with the purpose to operationalize an antibiotic stewardship program, which 
is often designed and introduced at a higher administrative level.  
  Figure 1.3.  The «holy trinity» of antibiotic resistance and spread (Owens, 2008)  





The implementation of evidence-based and updated antibiotic guidelines, establishing of clinical 
pathways and prescription audits with feedback to prescribing physicians are important and basic 
elements of the antibiotic stewardship program. Furthermore, in the work towards a more rational 
antibiotic use in hospitals, the magnitude of antibiotic utilisation must be calculated and 
presented on a regular basis. A proper system for surveillance of antibiotic use is therefore 
needed to facilitate and supplement a complete stewardship program. The ultimate purpose for 
collecting levels of antibiotic use on a routine basis is to expose inappropriate prescribing which 
may harm the patients, incur unnecessary costs for the health systems, and cause antibiotic 
resistance. Other reasons for surveillance are the possibility to identify factors that influence 
antibiotic use and to monitor the effect of implementation strategies. 41  
1.7. Legislative and strategic measures 
Norway has always had a strong legislative framework for the prevention of infectious diseases. 
A strong, but historically quite fragmented collection of laws on various communicable diseases 
was in 1994 incorporated into one single Act (“Smittevernloven”). 42 The § 4-7 of this Act states 
that measures to prevent hospital infections should be described in one central regulation. A 
regulation was then drafted and endorsed in 1996. As one of several impositions, this regulation 
lays down that every health institution shall have written guidelines for use of antibiotics i.e. 
updated recommendations for appropriate antibiotic use.  
Two subsequent national strategic action plans since 2003 (Figure 1.4, page 9) have listed 
multiple measures to combat antibiotic resistance and avoid the high levels seen in most other 
countries. The last revision in the plan for the period 2008–2012 43 determined that hospitals 
should have an antibiotic policy that includes reporting of the consumption of antibiotics and of 
antibiotic resistance.  
Two initiatives evolving from these strategic plans in recent years are particularly important for 
the improvement of antibiotic prescribing practices in Norwegian hospitals, namely  
1. the funding and establishment of a national “Competence centre for hospital antibiotic 
use” in 2011, and  
2. publication of a revised national guideline for hospital antibiotic use in 2013.





Unfortunately, the intentions regarding surveillance of antibiotic use and resistance at the 
hospital level have not been followed up. Moreover, it was decided to refrain from the 





Figure 1.4.  Norwegian national strategic plans for prevention of hospital infections and 






2. Epidemiology of antibiotic use 
2.1. Antibiotic use in the community (outpatient use) 
Norway. National statistics on antibiotic use have been available in Norway since 1974. The 
estimated figures have been based on gross annual sales of antibiotics to from wholesalers to 
pharmacies, and the utilization by patients in the community and patients treated in institutions 
have commonly been reported as one entity, at least before the year 2001 (see also “Wholesalers’ 
data”, page 17). However, a differentiation between ambulatory care and hospital care sales data 
has been made by subtracting deliverances to hospital pharmacies from the total number of doses. 
44 The gross consumption of antibiotics in Norway has been relatively stable at least since the 
early 1990ies but the pattern of use has changed (Figure 2.1). In a publication reporting data 
from the period 1980–1992, the national use of all systemic antibiotics varied between 14 and 
17 DDDs/1000 inhabitants/day. 45 Narrow-spectrum penicillins dominated, and the greatest 
concern expressed was a perceived high consumption of tetracyclines and co-trimoxazole.  
 






Bergan 25 published an overview of antibiotic use for the period 1994–1998, in which the  Nordic 
countries were compared. He found striking differences between these neighbouring countries 
with the highest levels of total antibiotic use in Iceland and Finland, the double of what was 
measured in Sweden and Norway. The Norwegian antibacterial consumption was an estimated 
14.4–15.4 DDDs/1000 inhabitants per day. The narrow-spectrum penicillins (ATC J01CE, 
benzylpenicillin and phenoxymethylpenicillin) accounted for ~40% of the total use. National 
figures from 2011 showed that the overall use – i.e. both in the communities and the hospitals – 
of antibacterial agents (excluding methenamine) had increased to 17.2 DDDs/1000 
inhabitants/day. The narrow-spectrum penicillins’ proportion of the total use has decreased 
significantly over the recent decades, to 26% in 2011, but altogether the penicillin group (ATC 
J01C) still accounts for as much as 50%. This is the result of a shift towards a relatively higher 
usage of penicillins with extended-spectrum and betalactamase-resistant penicillins. In the same 
period, the use of macrolides increased notably, which is a cause of concern.  
In contrast to most other countries, no oral form of the broad-spectrum antibiotics except 
fluoroquinolones (almost exclusively ciprofloxacin) is registered in Norway. Oral formulations 
of cefuroxime and penicillins with an enzyme inhibitor, notably amoxicillin/clavulanic acid, are 
widely used abroad and this fact is most certainly a factor contributing to the high resistance 
levels observed.   
Swedish national studies of antibiotic use go back as far as 1975. In an investigation mainly of 
the economic aspects of antibiotic use during the period 1975–1992, the conclusion was the 
following: “An increase of more than 25% in Swedish consumption of antibiotics during the 
study period was found. There is no obvious clinical explanation; indeed, improved hospital 
hygiene as well as decreased frequencies of some common bacterial infections should have 
resulted in a decrease in total consumption”. 46 
Obviously, the concern about inappropriate use of valuable antibiotics is not new. 
International data. In a study from 1997, Cars et al published a review of non-hospital antibiotic 
sales data from 15 EU member state (i.e. not including Norway) where the large dissimilarities 
in consumption first was documented. 47 Subsequently, international comparisons were made 
possible through the project European Surveillance of Antibiotic Consumption (ESAC). This 
organisation has undertaken several studies on outpatient antibiotic use. 48-59 Aggregated data, 






has been reported from Norway to the ESAC network since 2001. In the period 2001–2009, the 
national outpatient use was stable at 14.8–16.8 DID (DDDs/100 inhabitants/day). There might 
be some methodological limitations inherent in international comparisons, but the variation in 
pattern of utilization throughout Europe remains remarkable (Figure 2.2).   
 
 
2.2. Antibiotic use in hospitals 
In Norway, by now a continuous, standardized national surveillance of hospital antibiotic use 
has not been established. However, a national surveillance system on antibiotic resistance 
(NORM) has been established, and given rise to annual publications since 1999. These 
publications have given a short report on national antibiotic use, where the overall hospital use 
has been presented on the ATC levels 2 and 3 as DDDs/1000 inhabitants/day. 60 






Few surveys from Norwegian hospitals have been conducted. In one study, large differences in 
patterns of antibiotic use were demonstrated between two university hospitals for the period 
1993–2001. 61 The total use of antibiotics was similar in both institutions and varied between 
47–57 and 48–60 DDDs/100 bed days (BDs) per year, respectively. For the years from 1993 to 
1997, the penicillin group dominated (~70%) but extended-spectrum penicillins constituted 32% 
of total use in one hospital and 13% in the other. 62 By contrast, the latter used three times more 
second- and third-generation cephalosporins. This disparity was surprising since both were 
university hospital of comparable size. Furthermore, there were no evident differences in 
guidelines for antibiotic use and both hospitals had similar antibiotic resistance patterns. A 
possible explanatory factor, as the author duly emphasized, was that differences in the hospitals’ 
patient populations were difficult to adjust for. 
In another study, the use of antibiotics in 13 Norwegian hospitals in the period 1998–1999 was 
analysed. Neither hospital size or type nor geographical locations were found to be predictors 
for the scale of total antibiotic use. 63 The annual average registered was 45 DDDs/100 BDs.  
However, the relative use of antibiotic classes varied; smaller hospitals used less broad-spectrum 
agents than large hospitals and university institutions.  
 
Figure 2.3. Relationship 
between antibiotic use in 
ambulatory care (AC) 
and hospital care (HC) in 
Europe, 2002. 
Belgium (BE), Denmark 
(DK), Greece (GR), Finland 
(FI), France (FR), 
Luxembourg (LU), Sweden 
(SE), Estonia (EE), Hungary 
(HU), Malta (MT), Poland 
(PL), Slovakia (SK), 
Slovenia (SI),  Croatia 
(HR), Norway (NO) 






Through the ESAC network, accumulated national data are available for Norway, thus making 
comparisons with other European countries possible. However, only a few Norwegian hospital 
have participated in the ESAC subprojects where data from single hospitals have been analysed. 
ESAC presented an analysis of antibiotic consumption in hospital care for the six years 1997–
2002, based on a retrospective data collection. 51 In this review of 15 European countries, a 
striking correlation (Spearman coefficient 0.745; P= 0.002) was found when comparing 
antibiotic utilization in ambulatory care with hospital care antibiotic use (Figure 2.3, page 13).  
Moreover, a point-prevalence survey was conducted in 2006 that included 20 European 
hospitals. 64,65 Interestingly, the protocol aimed at identifying quality indicators, and the 
following were identified: 1) surgical prophylaxis not continued after 24 h; 2) antibiotic 
prescription documented in journal, and 3) no use of quinolones or third-generation 
cephalosporins for community-acquired pneumonia. In total, 30.1% (range 19%–59%) of all 
hospitalized patients received antibacterial treatment and the respiratory tract was the most 
frequent infection site.   
In Denmark, a nation-wide epidemiological study published in 2004 demonstrated an increase 
in hospital antibiotic use and changes in the patterns of use. 66 Total antibiotic use increased 18% 
from 1997 to 2001 (38.0 to 44.8 DDDs/100 BDs). Although antimicrobial resistance had not 
risen, there was a slightly higher proportion of broad-spectrum antibiotic use (second- and third-
generation cephalosporins, quinolones and carbapenems) in 2001 (19%) than in 1997 (16%).  
In a study from Sweden, Erlandsson et al 67 registered antibiotic use in 23 Swedish intensive care 
units during two weeks in 2000 and found that in tertiary care hospitals 84% (range 58%–87%) 
of patients were administered antibiotics compared to 67% of patients (range 35%–93%) in 
secondary hospitals and 38% in primary hospitals (range 24%–80%). In this study, a main 
finding was that the empiric prescribing was adequate when related to the bacteriological 
findings, probably because of a low prevalence of antibiotic resistance at that time. 68 A 
surveillance project of seven hospital departments in the Stockholm area used Internet for 
prescription aid as early as in 1999. The Internet site was also used to collect prescription data 
and served as a as a survey database. Total antibiotic use was 39–57 DDDs/100 BDs in 
departments of general internal medicine and 102–161 DDDs/100 BDs in infectious diseases 






In a questionnaire-based survey of 49 hospitals in southwestern France, the antibiotic use in 1999 
was on average 40.2 DDDs/100 BDs (range 6 to 70.4). 70 Psychiatric institutions were included, 
which explains the low values observed. Interestingly, broad-spectrum antibiotics, mainly 
penicillins with enzyme inhibitor, 13.6, third-generation cephalosporins, 2.5, and 
fluoroquinolones, 5 DDDs/100 BDs, were the most frequently used drugs. Units of intensive 
care, infectious diseases and haematology exhibited the highest levels of antibiotic use. 
de With et al 71 investigated antibiotic use in German university hospitals in the years 1998–
2000. Overall use was on average 60.1 DDDs/100 BDs for surgical services and there was an 
increase in use of 16% during the study period; corresponding figures for medical services were 
79.3 DDDs/100 BDs; an increase of 20%. The betalactam antibiotics, especially narrow- and 
intermediate-spectrum compounds, were the antibiotics most frequently used in surgical 
facilities (55%–73%) but lower figures were found for medical services (39%–60%). The 
fluoroquinolones were in second place; 9.6 DDD/100 BDs (range, 3.5–17.5) and 17.7 DDD/100 
BDs (range, 8.6–30.7) in surgical and in medical services, respectively. These authors also 
studied two cohorts of German intensive care units 72 and found significant differences in 
antibiotic use related to hospital’s affiliation and size, largely confirming the conclusions of the 
Swedish study cited above. 67 
It seems justified to state that at present (2013), no European country has established a permanent 
national surveillance of hospital antibiotic utilization. However, over the last decades several 
studies have been conducted, with use of different approaches for data collection and analysis. 
Accumulated sales data from reimbursement databases or pharmacy records have been the 
preferred sources for data acquisition. So far, electronic prescriptions databases have rarely been 
available. Standards for measurements of antibiotic use and reporting of results have been 
proposed, but an internationally accepted consensus has not been reached. However, the 
European surveillance network ESAC has established protocols both for longitudinal and point-
prevalence studies and those have been adapted and endorsed by the European Centre for Disease 
Prevention and Control (ECDC).   




3. Antibiotic surveillance methodology 
Surveillance in broader sense has been described by the WHO as being “the systematic collection 
and use of epidemiologic information for the planning, implementation, and assessment of 
disease control”. 73  
In a recent Norwegian strategic plan to combat antibiotic resistance, surveillance of antibiotic 
use was defined as a ”…continual, systematic gathering, analysis and interpretation of data on 
the use of antibiotics for people and animals for use in the planning, implementation and 
evaluation of measures for the optimization of this use.” 74 
There is a need for validated and robust surveillance methods in order to unveil areas of untoward 
antibiotic use in hospitals and of the methods of surveillance need adaption to the settings where 
they are planned to be used. The acquisition of data on hospital antibiotic utilization is often 
difficult because of the complexity of hospital structures and patient logistics. Moreover, when 
using the data for benchmarking, the surveillance results are difficult to interpret if case-mix and 
severity of underlying patient illnesses are not taken into account. 75,76  
Norwegian authorities have decided that continuous and active hospital surveillance of antibiotic 
use is a basic and important task that should be performed at both the level of the individual 
hospital and at the national level. 77 The main objective is to expose misuse, especially of the 
broad-spectrum antibiotics, which elicit resistance. 
3.1. Sources for data on antibiotic use 
Several levels of storage and distribution are involved before an antibiotic reaches the patient in 
a hospital (Figure 3.1, page 17). In 2004, the ESAC network published an overview of the 
methods used for their outpatient and hospital care surveys in the period 1997–2001. 44 Of the 
23 countries providing information about their sources for hospital antibiotic consumption data, 
15 used pharmacy distribution data while the remaining countries obtained data from 
wholesalers, manufacturers or marketing research companies. Only half of the 31 participating 
countries could deliver valid antibiotic consumption data for hospital care and only five countries 
for all registration years.  




Wholesalers’ data and pharmacy sales data have been used in Norway. Presently, for the routine 
surveillance of hospital antibiotic utilization, pharmacy sales data is still the preferred source in 
most European countries. 78,79  
Antibiotic use at the patient level, or “point of care”, is in most hospitals only possible to monitor 
through laborious and time-consuming manual registrations (e.g., chart reviews). Data mining 
based on electronic drug prescriptions has the potential to provide huge opportunities for 
antibiotic stewardship.  
 
 
3.1.1. Wholesalers’ data  
Historically, in Norway gross sales data from the manufacturers have been the sources for 
estimations of hospitals’ antibiotic consumption. A national institution, “Norsk Medicinaldepot” 
was established in 1953 with a monopoly with regard to wholesale and distribution of drugs. A 
new Pharmacy Act was passed in 2001, which privatized drug distribution. This led to the sale 
of the former national monopoly to one of three large pharmacy chains that are presently the 
main players in the Norwegian marked. However, the Pharmacy Act states that a delivery of 
drugs is the ultimate responsibility of the chains, and that any pharmacy acquiring a license is 
committed to ensure a safe delivery of drugs to the end user.    
With regard to hospital surveillance, the obvious shortcoming of the wholesalers’ data is a lack 
of information about the use within hospitals. Prior to 2001, the monopoly provided some rough 
estimates of consumption, thus ensuring some degree of consistency in the data reported. Since 
then, however, a more complicated situation has arisen as the liberation of the market allows for 
hospitals to acquire drugs from several sources. 
Figure 3.1 The chain of storage and distribution of antibiotics in Norway. 




3.1.2. Pharmacy sales to hospital wards 
A measure of the consumption of antibiotics in the hospital is possible to obtain through the 
collection and analysis of accumulated sales data from the hospital pharmacy to each hospital 
unit. There are variations in the distribution of drugs in different health care systems, the two 
main distribution lines being: 
1. Delivery in bulk to the wards or the unit stocks (“medicine rooms”), based on 
requisitions from the health care workers, a task usually performed by nurses. 
2. Prescription orders for individual patients are sent to the pharmacy, which prepare and 
deliver the doses to the units and wards.  
The first alternative has been the routine in most hospitals in Northern Europe, including 
Norway. 78 The drawback, both with use of wholesalers’ data and pharmacy sales data, is that 
information on individual patient prescriptions are not available. It is not possible to evaluate 
indications for antibiotic use, patient diagnoses or other information that is important for 
evaluation of appropriateness of prescriptions, such as drug doses and duration of therapy.  
 
3.1.3. Electronic hospital charts with prescription data 
In Norway as in most other European countries, the development of analytic tools integrated in 
hospital computer systems has historically been driven, for a large part, by administrative and 
economic incentives. This applies both to large clinical systems and to specialized pharmacy-
related applications. Thus, the focus has been on databases that contain little or no clinical 
information, or where the relevant information is difficult to access. An exception is Diagnosis 
Related Groups (DRGs) which relate to clinical information, but the use of this system is also 
financially motivated. For example, reliable dosing information regarding individual patient’s 
prescriptions has not been available for the purpose of pharmacoepidemiological studies and 
surveillance of antibiotic utilization.  
In the United States, information technology in hospitals, at least in some centres, has been 
helpful in providing tools for a more patient-based routine surveillance of the drugs that are 
actually administered to the patients. 80,81 This is mainly because the US health care system is 




based on a revenue of hospital services where all prescribed drugs are charged the insurance 
companies. By contrast, the European health care systems are more state-financed with a general 
transfer of money and resources to the hospitals.  
3.2. Overview of measurement units and terms 
As with most measurable entities, there will be numerous ways of defining units. However, while 
units of daily life (like time in minutes and hours, distance in yards or meters) are clearly defined, 
many measures related to quality indicators in hospital care are less precisely defined, and thus 
opening for various interpretations. The measure of drug (antibiotic) utilization belong to these 
less concise figures.  
 
3.2.1. The numerators: measures of drug amounts used 
The numerators in the relevant equations are the measures of use of an active antibiotic 
compound or use of a group of antibiotics. Most used is the WHO-determined Defined Daily 
Dose (DDD). However, DDDs have been criticised for not being accurate when used for hospital 
patients, who are often receiving higher doses per day than those given to patients treated outside 
hospitals. Alternative numerator measures, both for hospitalized patients and patients in the 
community, are listed in Table 3.1. 
 
Table 3.1. Main numerator measures (amount units) used in surveillance of antibiotic use. 
Numerator  References Used in settings 
WHO DDD (Defined Daily Dose) 82-84 All, international 
PDD (Prescribed Daily Dose) 85-89 Hospitals, (mainly national) 
Packages (i.e. fixed units, 








Defined daily doses (DDD) 
The DDDs as a general measurement unit for pharmaceutical compounds is, in essence, a joint 
Scandinavian invention that was first introduced at a WHO symposium held in Oslo, Norway, 
in 1969. 91 A need was recognised for an international unit of drug utilization, to make 
international comparisons meaningful and allow for pharmacoepidemiological studies across 
geographical borders. Even before the term “DDD” was coined, however, an “agreed defined 
dose” was used in an international study of antidiabetic drugs. 82 In 1979, Bergman et al. 
launched the term DDDs for audits of drug use in hospitals and, furthermore, suggested to relate 
the dose amounts to the length of hospital stay i.e. the number of patient bed days. 83 The first 
comprehensive national list of DDDs was published in Norway in 1975. 92 This unit of 
measurement has since been evaluated extensively 56,57 and has gradually become an 
international standard, although some countries have been slow to recognize and adopt this 
entity.  
The WHO Collaborating Centre of Drug Statistics Methodology (Oslo, Norway) maintains both 
the Defined Daily Dose (DDD) and the Anatomical Therapeutic Chemical (ATC) classification 
system. The WHO publishes new DDD definitions annually. Thus, in order to arrive at valid 
(comparable) results when temporal trends are explored the DDDs should be updated and be in 
accordance with the latest WHO definitions. 93,94 
95 
DDDs have successively gained acceptance internationally as a de facto standard unit for drug 
comparison studies. The system has an obvious advantage as it is owned and managed by the 
WHO. The organization maintains it, thus securing robustness and trustworthiness. Moreover, 
the DDD has a clear, uncomplicated definition and the single purpose of being a technical 
measurement unit. In the ATC/DDD guidelines, it is stated that DDDs for antibacterial 
substances are defined with respect to their use in mild to moderately severe infections that are 
mostly treated outside hospitals. Accordingly, DDDs have been shown to reflect ambulatory care 
antibiotic dosing 96 and doses used in the community. 
A DDD is a technical measurement unit, defined as “ – the assumed average 
maintenance dose per day for a drug used for its main indication in adults”. 




However, the WHO DDDs also have several limitations: 
x It does not always reflect the dose actually given to hospital patients; often the DDDs 
are set lower than the doses used in hospitals and consequently the hospital use of 
these antibiotics – measured in DDDs – will be too high.87  
x DDDs are not useful for measuring the antibiotic use in paediatric patients.97,98  
x DDD values do not take into account the frequently encountered clinical situation of 
dose adjustments, for example related to renal impairment 99 and weight differences. 
x DDDs for combination products represent a challenge. Usually the DDD definition is 
linked to the recommendation for use of the combination rather than the DDD of each 
ingredient, but this practice may differ between countries. 94    
 
Alternate dose units have been proposed that seek to alleviate some of these shortcomings. 
 
Prescribed daily doses (PDD) 
Some authors have suggested the use of “prescribed daily doses” (PDDs) as a measurement unit 
for hospitalised patients. 85-87,100 Various sources have been used to come up with reliable 
definitions for PDDs. Guidelines giving recommended dose regimens is one such source, another 
is the accumulated results of point-prevalence surveys from which may be PDDs calculated. One 
may encounter difficulties when trying to use point-prevalence surveys for estimation of a 
“correct” average daily dose in a defined patient population (e.g. hospital patients). For one, the 
number of antibiotic regimens examined to establish a certain dose must be high, and, secondly, 
it may be debated what is “the main indication” for each single antibiotic substance. This is 
related to the choice of the WHO definition – and if this is not chosen, what alternate criterion 
should be used? Lastly, to be optimal a PDD definition based on prevalence surveys must 
evaluate every regimen for dose adjustments related to for example organ failure, weight 
extremes and drug-drug interactions. 
 
Other numerator units 
Some alternate units in addition to the WHO DDD have been discussed but they have not 
obtained acceptance. 101 One proposed measurement unit is the number of prescribed packages 




of antibiotics. 24 This unit is of interest in countries where pharmacies dispense whole packages 
containing an amount of drug that corresponds to a full treatment course. The number of 
packages then approximates the number of prescribed antibiotic treatments. Since the measure 
is only applicable for orally administered drugs, it is intended for use in surveillance of 
community (outpatient) antibiotic use and not for use in hospitals. As has been demonstrated in 
some studies, 52,90 the number of packages (PID) give other – and mostly lower – results as 
compared with measures in WHO DDDs per 1000 inhabitants per day. It has been claimed that 
temporal trends may be reliably followed with this method, provided the number of units per 
package is not altered.  
Another unit is the MMD, the “minimum marketed dose”, i.e. the minimum daily dose that will 
produce a desired therapeutic effect. In practice, it is the lowest dose of an antibiotic declared by 
the manufacturer to give a cure for the infection at hand. Units such as “average daily dose” 
(ADD) or “equipotential dose” (ED) have also been suggested. 101 None of these units offers any 
advantage over DDD. They are less precisely defined and not in use. 
 
3.2.2. The denominators: units against which antibiotic use is related 
Doses per inhabitants per day (DID) 
For reporting outpatient antibiotic use, the amount in DDDs of antibiotics per day, usually related 
to 1000 inhabitants, has commonly been the measurement unit. The advantage is that usage is 
related to one day of use, that is to say the denominator relates to the numerator, which also 
describe the use of a daily dose of the drug. This makes DID a sensible measure to use in the 
community (outpatient) setting. As a measure for antibiotic use in hospitals, DIDs are less suited 
because the denominator does not relate to the hospital population but rather its related 
community population. It is often difficult to define the population that relates to a hospital (the 
“catchment area”), especially when several institutions operate within a large municipality or a 
city. 
 




Patient bed days (BDs) 
The patient bed days has been, by far, the most used denominator in indices of hospital antibiotic 
use. That length of stay relates to the exposure for antibiotics seems plausible. However, the 
antibiotic exposure is in no way proportional to the number of days hospitalized. For example, 
short average stays may imply high-density antibiotic exposure due to intensive treatment 
periods before discharging patients to lower levels of care, or short average stays may represent 
elective surgical treatments where little or no antibiotics are being prescribed. Conversely, longer 
stays in hospitals may be either low-risk rehabilitation (risk in terms of exposure to antibiotics) 
or high-risk intensive care treatments. 
 
Number of hospital discharges (admittances) 
The number of patient admittances and patient discharges will be equal provided the in-hospital 
patient deaths are registered in the hospital discharge statistics.  While the two terms may be 
used interchangeably as denominators, the norm has been to state the number of discharges. In 
most industrialized countries, the number of hospital discharges has increased and the average 
length of stay has decreased over time. This means that rates of antibiotic use are low when 
number of discharges is used as the denominator, while the opposite is true when patient bed 
days are used. Recognition of this fact is particularly important when temporal trends are 
evaluated. 
Table 3.2, page 24 gives an overview of the main denominators use in surveillance of antibiotic 
use; at least those currently relevant to use in European hospitals.  
 
Other denominator units 
Several other denominators have been suggested and some of these offer substantial advantages 
with regard to accuracy compared to denominators acquired from administrative databases. 
However, their routine use is restricted to health care systems that allow for more detailing of 
the antibiotic courses, for example to the level of individual prescriptions.  
Days of treatment (DOT). This is a measure of the duration in number of days for one antibiotic 
regimen, for a specific infectious condition, regardless of the number of substances used.  




Patient-days receiving antibiotics. This is the total number of days that a hospitalized patient 
receives antibiotics, irrespective of the number of substances, doses or administration. The term 
therapeutic courses is used synonymously. 102  
 
 
Days of therapy. Bacteria exert different strategies to resist the mechanisms of action of antibiotic 
substances. 104 In antibiotic regimens where two or more substances are combined – often for a 
discordant number for days – these effects are not properly accounted for when the number of 
patient days on antibiotics is used as denominator. For this reason, the term Days of therapy 
(DOT) 81 or Antibiotic days 105 has been introduced. The unit represents the accumulated number 
of treatment days for each separate antibiotic substance in the regimen. In particular, days of 
therapy may be a useful measurement unit if the effects on resistance development is a main 
study aim.  
Alternate denominators have been proposed such as the number of physician contacts or the 
number of insured individuals (for instances when the amounts of antibiotics are collected from 
reimbursement databases). 24 A finished consultant episode (FCE) is the time a patient spends in 
Table 3.2. Rates and ratios used to relate antibiotic use measurements for comparison 
purposes (adapted after Schechner et al 103). 
Measures Advantage(s) Disadvantage(s) 
Proportions of doses (related 
e.g. to total antibiotic use) 
Easy to collect, useful for 
clinicians 
Biased estimates from a 
public health perspective 
Doses per unit time  
(e.g., year) 
Easy to collect and interpret No account for difference in 
population size 
No account for occupancy or 
turnover 
Doses per occupied bed - or 
hospital days - per unit time 
(e.g., year) 
Accounts for occupancy Often difficult to collect; no 
account for turnover 
Doses per hospital 
admissions per unit time 
(e.g., year) 
Easy to collect and interpret; 
accounts for turnover 
Does not account for 
occupancy 




the care of one consultant in one health-care provider. For hospital in-patients this translates to 
“a period of healthcare under one consultant in one provider hospital”. 106 One hospital stay 
normally consists of a series of FCEs.  
The number of blood cultures 
drawn has been hypothesised as a 
useful surrogate marker for 
infection burden 107 and was 
found, in one small study, to be of 
value.  The argument is that use of 
this denominator would help 
overcome the inability of 
occupancy markers, such as bed 
days, with regard to adjustment 
for case-mix in hospitals. There 
has, to date, been no further 
publications to support this 
interesting proposal.  
3.3. “Standards of 
reporting” of antibiotic use  
There are numerous challenges 
and several pitfalls associated 
with the reporting of antibiotic 
use in hospitals. 100 
One set of standards has been 
proposed 88 ( Figure 3.1) but to 
date no guidelines have been 
published that have earned a 
normative status for how 
 Figure 3.1. Reporting recommendations (Kuster, 2008). 




antibiotic use should be measured and reported in the hospital setting.  
The WHO Collaborating Centre for Drug Statistics Methodology have, since 2003, published a 
thorough “Introduction to drug utilization research” 92 which is highly relevant for antibiotic use 
surveillance and research. However, the focus is strongly on the DDD methodology and the 
Anatomic-Therapeutic Index (ATC/DDD-system) for which maintenance the centre is 
responsible. 108  
3.4. Methods for surveying antibiotic use 
Pharmacoepidemiology is the study of drug use and drug effect. It is a relatively new field, 
combining aspects of clinical pharmacology (the study of clinical effect of drugs in humans) and 
epidemiology (the study of disease distribution and the factors determining diseases in the 
population). Antibiotic utilization in hospitals may be explored by different means, but two main 
epidemiological methods are commonly in use: prevalence studies and incidence studies. 
3.4.1. Prevalence surveys 
Prevalence is the number of cases with an active disease (or any other targeted determinant, for 
instance the number of therapeutic antibiotic courses) present in a defined population at a certain 
point in time. 109 The point prevalence rate is the number of these occurrences at a specific time, 
divided by the total number in the population under investigation – usually reported per one 
hundred or one thousand.   
In the investigation of the prevalence rates of patients’ antibiotic use, one may obtain valuable 
information by linking the physician’s prescriptions with the indications, i.e. the perceived 
infectious condition in individual patients. This information may be used to evaluate the 
appropriateness of antibiotic use, based on a set of criteria or adherence to published 
recommendations. Importantly, the ultimate propose is to provide feedback to the prescribers.  
Infection control in Norway has since 1991 focused on the prevalence of health-care acquired 
infections both in hospitals 110,111 and more recently in long-term care facilities. 112,113 An obvious 
next step is to add to such surveys the details about antibiotic use. An adequate registration of 
antibiotic specifics requires involvement of infectious diseases physicians or clinical 




pharmacists. 114,115 Several European studies of antibiotic use have been published, foremost 
from the ESAC (European Surveillance of Antimicrobial Consumption) project 52,64,65 – which 
has reported prevalence rates of antibiotic use in both hospital patients and outpatients across 
countries. Besides the mere reporting of rates to observe trends, 116,117 repeated prevalence 
surveys have been successfully used to investigate the importance of patient case-mix for inter-
hospital comparisons 118-120 and to evaluate the appropriateness of antibiotic prescribing. 121,122  
Even in its simplest form with little information registered, prevalence surveys of infections – 
with or without antibiotic use – to be undertaken, are valuable. Nevertheless, other kinds of 
surveillance activities should probably be prioritised. First, a positive effect has been 
demonstrated on health care workers hygiene and antibiotic prescription habits through the mere 
act of performing surveys. This has been called the “Hawthorne effect” of being under 
surveillance. 123,124 More importantly, prevalence surveys may reveal certain high-risk areas in 
hospitals that should be more extensively examined.    
A new method for point-prevalence surveys of hospital antibiotic use has recently been published 
by the ECDC in a light version, and as an extended protocol. 125 In this protocol, the well-proven 
ESAC methodology 126 is incorporated. In addition, the extended ECDC version include 
variables that should be registered for all hospitalized patients, such as demographics, a score 
system for underlying diseases, and the usage of urinary and vascular catheters. This allows for 
a far better characterisation of the complete patient population, not only for the patients infected 
and/or given antibiotics. As long as the methodological limitations are taken into account, 
116,118,127 risk factors may be identified and conclusions drawn that are relevant for surveillance 
interpretation. 119-122 
3.4.2. Incidence surveys 
Incidence is the number of new cases occurring over a defined period in a population. 109  In the 
study of infections, the population “at risk” of contracting the infectious disease(s) is chosen.  
Accordingly, for the study of antibiotic use, the population is the selection of individuals that 
may possibly be administered antibiotics. Because of the longitudinal nature of incidence 
surveys, the work load involved in conducting them may be formidable. This represents a 
challenge – not least if a prospective study design is chosen. The “gold standard” in the 
surveillance of antibiotic use is a manual, time-consuming registration of every antibiotic dose 




administered to each individual within a (hospital) population, preferably together with an 
evaluation of the appropriateness of the antibiotic use. Whereas this has often been done in 
specific and limited areas, for example in the prophylaxis of surgical infections, 38,128-131 routine 
surveillance in hospitals is rarely feasible because of resource limitations. Hospital-wide 
incidence surveys are currently not recommended from a cost-benefit perspective but may be 
appropriate for limited projects, for example to evaluate prescription practices. With the advent 
of electronic prescription systems, incidence surveillance of hospital antibiotic use may be 
possible and represent a great advance. 
 
 Analysis of accumulated consumption data 
The European Surveillance of Antibiotic Consumption (ESAC) network has published an 
overview of the methodology used by different European countries for accumulated antibiotic 
use in hospitals and in ambulatory care (outpatient antibiotic use). 44 Large differences were 
observed with regard to the sources of antibiotic utilization data, including manufacturers’ 
statistics, data from pharmaceutical companies, reimbursement data from insurance companies 
and social services, and sales data from pharmacies. The different data sources have inherent 
peculiarities that make comparisons difficult. In publications that attempt to benchmark 
antibiotic use between countries, these factors should be regarded. In Norway, the National 
institute of public health has been responsible for national statistics. The methods that have been 
used are described in chapter 3.1. 
 
Drug utilization methodology 
A longitudinal study method that rests on the ranking of the amounts of drugs used, rather than 
rates, was first used by Bergman to report drug utilization (DU) in Sweden. Later it was used to 
assess the quality of drug prescribing. 132,133 This assessment was applied to record general 
practitioners’ number of drugs within the 90% segment of their total lists of drug used. The 
quality of drug prescribing was measured by the proportion of the DU90% drugs that 
corresponded to substances recommended in official guidelines. In a study from 1999, Bergman 
et al investigated Stockholm hospitals’ antibiotic use by this methodology (see also page 14). 
The number of drugs used was shown to range from 9 to 13 in orthopaedic departments and from 




16 to 23 in infectious disease departments. Except for this study, DU90% has not – to our 
knowledge – been applied for antibiotic use prior to 2006. The method will be further discussed 
in relation to our own studies in Chapter 7.3, page 46. 





4. Aims of the thesis 
As described in the introduction, antibiotics are precious drugs that have saved lives and 
prevented suffering in an unprecedented scale. Their discovery have contributed immensely to 
the success of modern medicine. In the last decades, however, resistance has accelerated rapidly 
on a global basis. New antibiotics are rarely developed. One of the remaining strategies to combat 
resistance development is preservation of the existing drugs, in particular measures that can 
prevent inappropriate antibiotic use. Then it is vital to understand factors that determine 
inappropriate prescribing and to perform adequate surveillance of antibiotic utilization.  
The main objective of this thesis was to contribute to such knowledge by investigating the 
methods used in hospital antibiotic surveillance and, furthermore, to follow the consumption 
patterns of the various antibiotics used in hospitals and to reveal temporal utilization trends. We 
also aimed to explore the factors that explain variations in antibiotic utilization between hospitals 
in order to facilitate antibiotic stewardship efforts.  
 
The specific aims were as follows: 
x To investigate the reliability of data sources that antibiotic utilization measurements 
are based on – pharmacy sales data versus ward stock accounting.  
x To investigate how choice of dose unit (numerator) – WHO DDDs versus hospital 
adjusted DDDs (haDDDs) – affects hospital antibiotic surveillance results.   
x To evaluate how the denominator – number of bed days and number of discharges – 
affects hospital’s antibiotic surveillance results.    
x To investigate temporal trends in use of antibiotics in Norwegian hospitals, with 
special emphasis on broad-spectrum antibiotics. 
x To identify modifiable and non-modifiable factors that are decisive for hospital 
antibiotic use.  





5. Material and methods 
The methods used to acquire data for this thesis have been chosen with the intention that they 
should be simple and reproducible. To be useful for a future national surveillance system, all 
data should be obtained from easily accessible and validated sources. We have used the 
methodological recommendations set by the ESAC collaboration in the surveys of antibiotic use 
in Europeans countries 44 and have also adhered to the standards for antibiotic surveillance 
published by Kuster 88 (see “Standards of reporting” of antibiotic use” on page 25). 
5.1. Data on antibiotic use  
Selection of antibiotic agents  
We used the range of antibacterial agents chosen by the “ESAC II Hospital Care Study Group” 
in their 2009 point-prevalence survey 65 and, in addition, we adhered largely to the protocol for 
the ESAC longitudinal hospital care survey. 134 Being part of the study group, our centre at the 
time – Aker university hospital – had access to the ESAC protocol. We adopted their selection 
at an early stage because it appeared sensible to implement a future European standard. 
Accordingly, for all papers in this thesis, the selected systemic antibacterial agents were the 
ATC/DDD group J01 except J01XX05 (methenamine, a urine antiseptic widely used in 
Norway), as well as A07AA09 oral vancomycin, J04AB02 rifampicin, and P01AB01 oral 
metronidazole. These were denounced “total antibiotics”. Two additional subgroups of antibiotic 
classes were defined as “broad-spectrum antibiotics” (second- and third-generation 
cephalosporins, fluoroquinolones, carbapenems, and penicillins with enzyme inhibitors) and “all 
penicillins” (penicillinase-sensitive, penicillinase-resistant, and extended spectrum penicillins). 
Defined daily doses (DDDs) 
Antibiotic sales data used in all the analyses that are part of this thesis originate from a standard, 
commercial pharmacy system (FarmaPro® version 4.1.0a, NAF-data Corp., Norway). By the use 
of a “statistical factor” assigned to each single drug package and taking into account the number 
of items sold, the number of DDDs for each transaction are automatically calculated by the 
pharmacy data system.   





The amounts of antibiotics were reported as DDDs according to the 2007 135 (paper I and II) and 
2011 95 (paper III and IV) WHO definitions. Changes in defined daily doses (DDDs) made by 
the WHO during the study period were adjusted for as recommended by the WHO. 93 For 
substances available both as a parenteral and oral formulation, the sum of both were reported 
unless stated otherwise. No hospital in Norway has yet implemented electronic data systems that 
monitor daily prescriptions to individual patients. Thus, neither “days-of-therapy” (DOT) 81 nor 
the actual “prescribed daily doses” (PDDs) 89 are obtainable on a routine basis and were not 
investigated in our studies. 
Hospital-acquired defined daily doses (haDDDs) 
We introduced the term hospital-adjusted defined daily doses (haDDDs). Twenty-seven haDDD 
assignments were undertaken for 24 antibiotic substances (ATC level 5), that is to say, for the 
three substances cloxacillin, dicloxacillin and trimethoprim both the oral and the parenteral 
formulations were adjusted. Also for metronidazole, both the oral and the parenteral formulations 
were adjusted but these have different ATC codes. Rectal formulations of metronidazole were 
assigned to the oral administrated group since they accounted for only 0.6% of the total doses of 
antibiotics and 2.7% of non-parenteral antibiotic doses. The process of antibiotic dose adjustment 
is described below. 
Co-amoxiclav (amoxicillin + clavulanic acid) have been considered to be too low set by the 
WHO in studies from Europe, where it is the most used drug in many countries. The drug is not 
registered in Norway, and the consumption during the six study years was very low (3 285 oral 
and 394 parenteral WHO DDDs, 0.024 % of the total use). Moreover, no indications for the use 
of the drug existed in any guideline, and we therefore chose to omit it from the list of altered 
WHO DDDs, together with other unregistered flucloxacillin and ampicillin/sulbactam. Because 
these antibiotics were rarely used, omitting them from dose alterations does not change our 
overall results and conclusions. 
The assignment of haDDDs was done, true to the WHO definition, by estimation of the 
therapeutic maintenance dose of each drug in adult individuals without a renal impairment. The 
recommended antibiotic regimens were acquired from one national guideline (published 2001) 
and from four regional guidelines for hospital antibiotic use (published 2006 – 2009). In a few 
cases where the doses for the same conditions differed in the guidelines, an average dose was 
estimated. The exact haDDDs (in grams) were calculated from the average daily doses 





administered for the most common indication of the agent, evaluating one moderately severe and 
one severe infection separately. A specific haDDD was set as the estimated mid-value between 
the dose recommendation for a severe and for a moderately severe infection. To arrive at some 
of these mid-values, we explored an anonymised dataset from a large Health Region of South-
Eastern Norway. From the main ICD-10 diagnoses, we estimate the ratio between the 
occurrences of several common moderately severe and severe infections, for which guidelines 
recommended the antibiotic substances in question (see Methods, Paper III). Infectious 
conditions of minor severity were disregarded because these are infrequently seen in hospitalized 
patients.  
Data acquisition and processing  
Sales data for antibacterial agents were extracted from the data systems of single hospital 
pharmacies and from a central national database. All pharmacies in Norway, in and outside 
hospital, use the commercial system Farmapro®. Paper I analysed five high-consumption wards 
at Aker university hospital, Paper II eight Health Enterprises of the former Eastern Norway 
Regional Health Enterprise, while Papers III and IV included data from somatic departments of 
all 22 HEs in Norway. In all studies, we excluded specialized private institutions for elective 
orthopaedics, rheumatology, heart surgery and rehabilitation. Neither were psychiatric wards and 
institutions and substance abuse units included. 
For Papers I and II, the antibiotic datasets were imported from the local hospital pharmacies’ 
Farmapro® data systems. After receipt, the data were quality assessed by means of spot-checking 
against the original data sources. The first author undertook this quality check. The data files 
were imported into a Microsoft Access® database (Paper II) and analysed in Microsoft Excel® 
by means of pivot tables. 
For Paper I, two data sets on broad-spectrum antibiotic use were compared for the same 26 weeks 
period (from Oct 2006 to Apr 2007): 
1. Pharmacy sales data (from Farmapro®) at five wards at Aker university hospital.  
2. A weekly ward stock accounting done at the same five wards by a clinical pharmacist. 
The ward stock accounting was a manual counting of the ward stock of broad-spectrum 
antibiotics, undertaken at the same time every week. Parenteral and oral formulations of the study 
drugs (broad-spectrum antibiotics) were analysed separately. 





For Paper II, a complete antibiotic dataset was imported from each single hospital pharmacy 
situated at eight Health Enterprises (HEs) of the former Eastern Norway Health Region. These 
HEs represent a multitude of wards and units, and an objective of the study was to allocate 
antibiotic use to clinical specialties within the HEs. Accordingly, an extensive and manual code 
mapping was necessary in order to connect the antibiotic (pharmacy) data with the administrative 
data (bed days and number of discharges) – see “Administrative data” below.   
For Papers III and IV, we obtained the dataset on antibiotic agents from a centralized database 
maintained by the national Hospital Pharmacy Enterprise (“Sykehusapotekene HF”). This 
database contains accumulated data since 2006. The data system imports in real-time sales 
figures from all Norwegian hospital pharmacies and contains relevant information on all drugs 
that are dispensed (sold) to the hospitals wards and units. The system has largely been in function 
since 2010.  
5.2. Administrative data and patient-related factors 
Data on the length of hospital stay (LOS) and the number of patients treated (discharges) were 
derived from the official National Patient Registry, “Norsk Pasientregister” (NPR). A hospital 
stay lasting > 24 hours was defined as an in-patient treatment, and length of hospital stay (LOS) 
was calculated as the difference between date of discharge and date of admittance.   
For Paper II, a link between the antibiotic pharmacy sales data and the administrative data was 
established through a meticulous, manual mapping of hospital units within each Health 
Enterprise by means of linked tables in a Microsoft Access database (see also chapter 7.1). This 
labour-intensive manual procedure was a consequence of a complete lack of coding 
standardization for the hospital wards, both within and between the Health Enterprises and the 
hospital pharmacies. The effort was essential, however, to allocate a correct clinical specialty 
category to all the wards, and to be able to distinguish hospitalized (in-patients) from ambulatory 
and day-care patients. The wards were then assigned their main clinical specialties, which 
subsequently became a main grouping variable in the study. After assembly of all variables in 
the Excel spreadsheets, datasets were exported to statistical software for the final analyses.  
In Papers III and IV, we investigated the antibiotic use in somatic wards of the 22 Norwegian 
HEs. They constitute the whole Norwegian hospital population except for some small private 
and specialised institutions. The sources of administrative and clinical data were from the NPR, 





as in Paper II. However, we could not perform any allocation of data to the specialties/wards 
within the HEs as had been done in Paper II. With the routinely acquired information in these 
public databases such analyses were not possible to undertake. Furthermore, we were not able to 
distinguish the number of day-care patients from hospitalized patients in the analyses for Papers 
III and IV.  
An additional source of information for the Paper IV was the database of Statistics Norway, the 
data from which we established some of the explanatory variables for the multivariate analyses, 
such as the individual HE’s employment rates for registered nurses and physicians. The national 
database contained data on antibiotic use for 22 Health Enterprises over a period of six years 
(2006–2011). Thus, 132 data records were the basis for the analyses. Fourteen variables had been 
selected and were analysed in 12 multiple linear regression models with regard to their 
explanatory value for the variances of three dependent (outcome) variables, these being the HE’s 
use of all antibiotics, broad-spectrum antibiotics and all penicillins. For each of these three 
outcome variables, four indices were used separately in the regression models: WHO DDDs per 
100 bed days and per 100 discharges, and hospital-adjusted DDDs (haDDDs) per 100 bed days 
and per 100 discharges. 
5.3. Hospitals’ antibiotic resistance 
Information about antibiotic resistance for common pathogens in blood cultures was obtained 
from the annual reports from the national microbiological surveillance system NORM/NORM-
Vet. 136 In the NORM system, all 23 microbiological laboratories in Norway adhere to an 
identical sampling strategy, applying identical criteria for the inclusion of microbial strains (one 
isolate per patient and blood culture episode). Bacterial species are identified by standard 
methods and susceptibility tested by disk diffusion and E-test using breakpoints established by 
EUCAST (The European Committee on Antimicrobial Susceptibility Testing).  
Resistance data from NORM/NORM-Vet report from 2007 60 was used for the study periods in 
paper II and the report from 2011 for the Papers III and IV. 137 The individual HEs maintain no 
local databases that enable the acquisition of detailed antibiotic resistance data. Consequently, it 
has not been possible to investigate any link between antibiotic consumption and antibiotic use. 





5.4. Statistical analyses 
STATA ® software version 11 and 12 was used for all statistical analyses in the thesis. Microsoft 
Excel ® was used for labelling and preparing of data for export to STATA ® and all ranking of 
variables for drug utilization (DU 90%) analyses. The Table 6.1 (page 36) gives a summary of 




The Bland Altman plot. The methodological considerations for appraising the agreement 
between one measurement unit and another unit, perceived as the “gold standard”, were reviewed 
by Bland and Altman in a seminal work (1986). 138 A general error in statistical analyses is to 
report the Pearson’s correlation coefficient as a measure of agreement between methods. A very 
Table 6.1. Statistical analyses in the thesis, overview according to purpose and paper. 
Method Purpose in the study Paper 
Bland-Altman statistics Visual (graph) and measure (limits of agreement) of the 
reliability of one method of measurement, compared to a 
perceived “gold standard”. 
I 
 
Intraclass correlation  
 
Assesses the degree of agreement of two methods of 
measurement applied on the same sample. 
I 
 
Student-T test (two-sided) Compare continuous variables between groups. II, II. 
IV 
Single linear regression Determines the contribution of one (independent) factor to 




Investigates correlations between numerical variables.  II, III 
Analysis of variance 
(ANOVA) 
Evaluation of trends in antibiotic use. III 
Kruskal-Wallis rank-sum test Trend analysis if group variances are large, (as determined 
by the Bartlett’s test for equal variances). 
III 
Multiple linear regression Determines the contribution of several (independent) 
factors to a single outcome (dependent) variable. 
IV 





poor agreement may produce very high correlations, e.g. the agreement between the series 10-
20-30-40 and 100-200-300-400 is very poor, but the correlation is 1.0. The Bland Altman method 
is to plot, in an x-y diagram, the difference in parallel values of the two measurements against 
their mean value. The term “limits of agreement” was introduced by the authors, defined as the 
± standard deviation (SD) of the average difference between the methods (provided these are 
normally distributed). It will then be a clinical decision to determine whether the values range, 
which represents the 95% error range by the new method, is clinically relevant or not. In a visual 
inspection of the plot, one may also determine if the differences are similarly distributed for 
various ranges of means – that is, if the limits of agreement remain constant or changes 
significantly for low and high mean values. In our study, the ranges were the percent DDD 
representing ± one SD of the average mean DDD values.  
Intraclass correlation coefficient (ICC). For determining agreement between the two methods for 
measurement, we also used the ICC. 139 Variance in ICC is relying on the pooled variability of 
the two matched measurements, and not the variability in each group as in Pearson’s correlation. 
The objective of the ICC is to determine how much of the total measurement variation that is 
due to difference between the methods and how much is due to difference in measurement for 
each method (the “within” variation). The mean square of the differences between the values 
(MSB) and the mean square within them (MSW) are used for calculation 
 ܫܥܥ ൌ ெௌ஻ିெௌௐெௌ஻ାெௌௐ    
If the “within” difference MSW is very small, ICC will be close to one. Conversely, if MSB = 
MSW, ICC will be zero and there is absolutely no agreement between the measures. 
Interpretation of ICC as for Pearson’s correlation, with an ICC value of > 0.7 considered to 




Linear regression. A linear regression procedure (‘regress’ in STATA) was used to analyse the 
temporal trends for different groups of antibiotics (total antibiotic use, broad-spectrum 
antibiotics and all penicillins). The regression gave the regression coefficient with confidence 
intervals, i.e. the changes in DDDs per year, and the effect size (or coefficient of determination) 





which, in linear regression, is interpreted as a correlation coefficient. Lastly, an adjusted R2 gave 
the strength of the relationship for the equation, which is a conservative estimate of how large a 
part of the variation in antibiotic use could be explained by the time factor. 
 
Paper III 
We used Pearson correlation coefficients (STATA ® procedure ‘pwcorr’) for univariate analyses 
of correlation between numerical variables. The Chi-square test was used for categorical 
variables in contingency tables. 140 For differences between group means of normally distributed 
numerical data, a Student-T test (STATA procedure ‘ttest’) was used, while analysis of variance 
(STATA procedure ‘anova’) was used for multiple-group analysis. For all analyses, a two-tailed 
P < 0.05 was considered statistical significant. 
For the drug utilization 90% (DU90%) ranking, 133 antibiotic substances and groups were ranked 
according to their total amount of DDDs (respective haDDDs) over the study period. The list 
was limited to the antibiotics that, accumulated, fell within 90% of the total antibiotics used. 
 
Paper IV 
The Pearson correlation coefficient was calculated as described for Paper III. Multiple linear 
regression (STATA ® procedure ‘regress’) was used for all 12 regression models with a 
backward stepwise approach. As a test for collinearity between independent variables, we 
calculated the variance inflation factor 8’vip’) at each regression step and rejected the variable 
with the largest vif  value until no variable had a vif > 5.141 The coefficient of determination R2 
was calculated for all regression models. R2 may be defined as the proportion of possible perfect 
prediction represented by the regression model. 142 Because of a relatively large number of 
independent variables, the adjusted R square (aR2) was calculated for each regression model to 
show how well it fitted the data. For all analyses, aR2 > 0.3 was considered a strong correlation, 
i.e. inferring a high degree of causal influence. A two-tailed P-value < 0.05 was set as a limit for 
statistical significance.  
  





6. Synopsis of the studies 
Here, we give the synopsis (abstracts) of the four publications that this thesis is based on. To aid 
in the interpretation of our findings, an extra Table 6.1 (page 41) for the Paper II and a Figure 
6.1 (page 42) for the Paper III supplement the results given in the published articles. 
6.1. Paper I 
Background: Antibiotic consumption in hospitals is commonly measured using the accumulated 
amount of drugs delivered from the pharmacy to ward held stocks. The reliability of this method, 
particularly the impact of the length of the registration periods, has not been evaluated and such 
evaluation was aim of the study. 
Methods: During 26 weeks, we performed a weekly ward stock count of use of broad-spectrum 
antibiotics – that is second- and third-generation cephalosporins, carbapenems, and quinolones 
– in five hospital wards and compared the data with corresponding pharmacy sales figures during 
the same period. Defined daily doses (DDDs) for antibiotics were used as measurement units 
(WHO ATC/DDD classification). Consumption figures obtained with the two methods for 
different registration intervals were compared by use of intraclass correlation analysis and Bland-
Altman statistics. 
Results: Broad-spectrum antibiotics accounted for a quarter to one-fifth of all systemic 
antibiotics (ATC group J01) used in the hospital and varied between wards, from 12.8 DDDs per 
100 bed days in a urological ward to 24.5 DDDs in a pulmonary diseases ward. For the entire 
study period of 26 weeks, the pharmacy and ward defined daily doses figures for all broad-
spectrum antibiotics differed only by 0.2%; however, for single wards deviations varied from -
4.3% to 6.9%. The intraclass correlation coefficient, pharmacy versus ward data, increased from 
0.78 to 0.94 for parenteral broad-spectrum antibiotics with increasing registration periods (1-4 
weeks), whereas the corresponding figures for oral broad-spectrum antibiotics (ciprofloxacin) 
were from 0.46 to 0.74. For all broad-spectrum antibiotics and for parenteral antibiotics, limits 
of agreement between the two methods showed, according to Bland-Altman statistics, a 
deviation of ± 5% or less from average mean DDDs at 3- and 4-weeks registration intervals. 
Corresponding deviation for oral antibiotics was ± 21% at a 4-weeks interval. 





Conclusions: There is a need for caution in interpreting pharmacy sales data aggregated over 
short registration intervals, especially so for oral formulations. Even a one-month registration 
period may be too short. Antibiotic consumption in hospitals is commonly measured using the 
accumulated amount of drugs delivered from the pharmacy to ward held stocks. The 
methodological issue addressed in this study was to assess the reliability of this method for short 
registration intervals periods.  
6.2. Paper II 
Objectives: Although antibiotic use and resistance are low in Norway, the situation risks 
changing for the worse. We investigated trends in antibiotic use and assessed them in relation to 
antibiotic resistance in Norway. 
Methods: We drew on hospital pharmacy sales data to record antibiotic use from 2002 to 2007 
in eight hospitals serving 36% of the nation’s population. Antibiotic use was measured using 
different indices with defined daily doses (DDDs) as the numerator (WHO ATC/DDD 
classification). 
Results: Total antibiotic use increased from 1.02 to 1.30 DDDs/1000 inhabitants/day (DIDs) 
and from 61.7 to 72.4 DDDs/100 bed-days (BDs) (17.4%); related to the number of discharges, 
no significant DDD change was shown. Their use in core units (adult intensive care units, 
recovery/post-operative wards and departments of internal medicine and surgery with all 
subspecialties) increased from 64.1 to 80.8 DDDs/100 BDs (26.1%) and by 3.1% related to the 
number of discharges. The total use of broad-spectrum antibiotics increased by 47.9% when 
measured as DDDs/100 BDs, and by 19.1% based on the number of discharges; the 
corresponding figures for core units were 60.5% and 31.2%, respectively.  
The total use of different antibiotic classes for all specialties in 2007 and the changes in use since 
2002 are given in Table 6.1, page 41. 
Conclusions: There was a substantial increase in total antibiotic use, and an even more 
pronounced increase in the use of broad-spectrum antibiotics, which seems unjustified 
considering the current low antibiotic resistance in Norway. 
















6.3. Paper III 
Objectives: To investigate effects on surveillance results of hospital antibiotic use when WHO 
defined daily doses (WHO DDDs) are adjusted to doses recommended for hospitalized patients 
[hospital-adjusted defined daily doses (haDDDs)]. 
Methods: Data for antibiotic use in 2006–11 for all 22 Norwegian Health Enterprises were 
analysed with both WHO DDDs and haDDDs as numerators. The haDDDs were determined 
from recommendations given in regional and national guidelines on antibiotic use in hospitals.  
The two ways of calculating the amount of antibiotic use were compared, with either the number 
of bed days (BDs) or the number of discharges as the denominator. The drug utilization 90% 
methodology was applied for ranking the use of the various antibiotics. 
Results: DDD adjustments altered the figures for total antibiotic use from 67.1 WHO DDDs/100 
BDs to 49.3 haDDDs/100 BDs (–26.4%). The most marked difference was found for penicillins: 
31.1 WHO DDDs/100 BDs versus 13.4 haDDDs/100 BDs (–56.8%) (Figure 6.1). The 
corresponding figures for broad-spectrum antibiotics were 17.3 and 15.5 (–10.4%), respectively; 
Figure 6.1. 





for these antibiotics, the conversion changes varied significantly between institutions, from 
–16.7% to –3.3%. Ranking antibiotic use based on haDDDs resulted in higher positions for 
metronidazole, cefuroxime, cefotaxime and cefalotin/cefalexin compared with the WHO DDD-
based ranking, where the penicillins dominated. 
Conclusions: The low-set WHO DDDs for penicillins caused skewed surveillance results that 
concealed the real magnitude of broad-spectrum antibiotic use and distorted interhospital 
comparisons. For surveillance of antibiotic use in hospitals, WHO DDDs should be 
supplemented with haDDDs. 
6.4. Paper IV 
Objectives: To identify factors that may contribute to differences in antibiotic use in hospitals. 
Based on pharmacy sales data (2006–2011), use of all antibiotics, all penicillins, and broad-
spectrum antibiotics was analysed for 22 Health Enterprises (HEs).  
Methods: Antibiotic utilization was measured in World Health Organization defined daily doses 
(DDDs) and hospital-adjusted (ha)DDDs, each related to the number of bed days (BDs) and the 
number of discharges. Fourteen potentially explanatory variables for the observed antibiotic use 
were examined in 12 multiple linear regression models with four different measurement units: 
DDD/100 BDs, DDD/100 discharges, haDDD/100 BDs and haDDD/100 discharges.  
Results: Eight explanatory variables were independently associated with antibiotic use, but with 
a variable pattern depending on the regression model. High levels of nurse staffing, high 
proportions of short (< 2 days) and long (> 10 days) hospital stays, infectious diseases being the 
main ICD-10 diagnostic codes, and surgical diagnosis-related groups were correlated with a high 
use of all antibiotics. University HEs had a lower level of antibiotic utilization than other 
institutions in all 12 models, and carried a high unique explanatory strength. The use of broad-
spectrum antibiotics correlated strongly with short and long hospital stays. There was a residual 
variance (30%–50% for all antibiotics; 60%–70% for broad-spectrum antibiotics) that our 
analysis did not explain.  
Conclusions: The factors that predicted hospital antibiotic use were mostly non-modifiable. By 
adjusting for these factors, differences between hospitals may be more confidently acted upon. 
The residual variation is presumed to largely reflect prescriber-related factors. 





7. Discussion of antibiotic surveillance methods  
Paper I is a study of the reliability of pharmacy sales figures as a data source in the recording of 
hospitals’ use of antibiotics, in particular the use of broad-spectrum antibiotics. The Papers II–
IV report trends in the hospital use of antibiotics, however the main purpose of these studies was 
to investigate methodological aspects and to identify factors that may explain differences in 
antibiotic utilization patterns between institutions.  
These methodological issues are discussed in the following.  
7.1. Reliability of pharmacy sales data 
We conclude from the results of Paper I that pharmacy sales data were reliably reflecting the 
number of DDDs of broad-spectrum antibiotics (BSAs), dispensed to patients in five high-
consumption wards at a medium-sized university hospital and with a registration period of six 
measured months. For shorter registration intervals, however, measures of BSAs were less 
reliable for oral than for parenteral formulations. The pharmacy sales measures for parenteral 
BSAs, as a group, were reliable over the time intervals 1, 2, 3 and 4 weeks. For oral formulation 
of ciprofloxacin even the 4-week interval seemed to be too short. This is probably a consequence 
of oral formulations being cheaper and less voluminous than parenteral antibiotics, and thus more 
prone to excessive stockpiling.  
The short registration intervals for antibiotic utilization investigated by us are highly relevant for 
antibiotic resistance studies using time-series analyses 143-145 and for studies of the effect of 
interventions to improve antibiotic use, for which the interrupted time-series methodology is also 
relevant. 146-148 One of our objectives was to use the results in a subsequent study of a possible 
relationship between the antibiotic use and antibiotic resistance. Unfortunately, with limited 
resources, we could not acquire data of sufficient quality from the laboratories of microbiology.  
We think our results are of general interest, not least because some authors have recommended 
routine surveillance of ward-stock antibiotics with use of one-month registration intervals to 
detect the patterns and time trends in hospitals’ antibiotic utilization. 149,150 Furthermore, hospital 
administrators are increasingly requesting results dealing with consumption of antibiotics. 





Probably, such data inquiries will be even more frequent in the future, both for hospital quality 
benchmarking purposes and for budgeting and economic planning.   
The reliability of pharmacy sales data as a measure of patient antibiotic use in hospitals has not 
been thoroughly investigated before. Although the system of ward stock piling of drugs is the 
standard in northern Europe, it has been reported that in 39% of southeast European hospitals 
the pharmacies dispense the antibiotics directly to the patients. 78 Solano et al 151 found poor 
correlation between antibiotics dispensed and antibiotics administered in an Australian ICU, 
based on reviews of sales data and patients chart records, respectively. Interestingly, for oral 
ciprofloxacin they found an exceptionally high short-term deviation of 48% between the two 
measurements.  
We conclude that short-term evaluation of broad-spectrum antibiotic use based on pharmacy 
sales data should not be advocated. However, the validity of our findings for other types of 
hospitals may be questioned, especially so when it comes to other countries. Still, for 
Scandinavian hospitals – given their relatively low consumption of BSAs – caution should be 
exercised when short-term fluctuations are recorded and interpreted.  
7.2. Bed days versus discharges as denominator unit 
The results of Papers II and III confirm the importance of reporting the antibiotic use with 
different measurement indices.  
A main result is the lower increase in utilization of total antibiotics and BSAs when DDDs are 
related to number of discharges as compared to using hospital bed days, that is to say with 
different denominator units. Several authors have pointed out that the calculation and reporting 
of both indices are important in the interpretation of data on antibiotic use. 79,86,88,89,100 Largely, 
one may hypothesise as to the correct interpretation of these antibiotic use indices. One 
conceptual approach may be that the “truth” lies in the middle, between measurements related to 
doses per patient bed days and doses per patient discharges. For certain hospital settings, it has 
been proposed that an intensification of antibiotic use per patient bed day may be associated with 
shorter duration of antibiotic therapies, a situation that may lower the resistance pressure exerted 
by the antibiotics. 79  





It is of particular importance to report temporal trends by use of both the number of bed days 
and number of discharges, since the average length of stay (LOS) has decreased considerably in 
most hospitals. The Hospital Trust system, introduced in Norway in 2002, has had a particular 
focus on costs and coding based on diagnosis-related groups (DRG). This has accelerated a 
tendency towards shorter LOS, thereby allowing for an increased number of hospital stays.  
The substantial result differences reported in Papers II and III by use of the two different indices 
(denominators) strongly support the view that both measurements should be used, not only in a 
scientific context but also in the routine surveillance. 
7.3. WHO DDDs versus hospital adjusted DDDs 
In Paper III, we used a countrywide database of 22 Health Enterprises’ antibiotic use to examine 
the effect of introducing hospital-adjusted DDDs. The results found with the use of this index 
was compared with those obtained based on WHO DDDs.  
The high proportion of penicillins used by Norwegian hospitals and the particularly low set 
WHO DDDs for penicillins was the main reason why the surveillance results became 
significantly different with use of haDDDs. The consumption of all penicillins was less than one 
half and that of broad-spectrum antibiotics 9/10 of the findings based on WHO DDDs.  
No significant differences in temporal trends could be demonstrated for the national utilization 
of antibiotics, which means that the WHO DDD to haDDD conversion apparently did not 
influence the main conclusions regarding the development over time. However, there were inter-
institutional differences, in particular for broad-spectrum antibiotics. In addition, although the 
increase over time for all penicillin use was similar with WHO DDDs and haDDDs, there were 
diverging results for subclasses of penicillins.  
We found that the use of haDDDs had an impact on drug utilization ranking (DU90%). The 
DU90% methodology has been proposed by Zarb et al, who used it for analyses of temporal 
trends when comparing antibiotic use in European hospitals.152 In that study, the method was 
deemed best suited in the evaluation of a single hospital’s temporal trends and when comparisons 
were made between hospitals with similar characteristics and antibiotic formularies. We used 
the DU90% method in a novel way, namely to demonstrate the implications of hospital dose 
adjustments with regard to surveillance results. The method proved especially useful in this 





context, since the alterations in ranking could be visually evaluated and thus were easy to 
interpret.  
Importantly, we demonstrated a more pronounced diversity in surveillance results with the 
DU90% ranking method when haDDDs were applied. Thus, the use of a more correct daily dose 
definition unveils more surveillance details. 
A common challenge when attempting to establish alternate dose definitions is to find convincing 
methods to determine the “correct” dose for all antibiotics used. In countries where electronic 
prescription data are not available at the patient level (i.e. in most European countries) two 
methods have been used. One is to use doses recommended in guidelines, as we have done, the 
other is to apply results from repeated prevalence surveys of antibiotic use to calculate locally 
administered daily doses for various indications. The latter option has not been available in 
Norway because, up until now, only few hospitals have participated in the national point-
prevalence surveys.  
The WHO DDD-based method for recording antibiotic use in hospital patients has been 
evaluated previously. A one-year survey in 2001 from a French hospital with the number of 
antibiotic days of treatment (DOT) available, calculated prescribed daily doses (PDDs) by 
dividing WHO DDDs with DOT for various antibiotic substances. 87 They found a 40% 
overestimation of treatment days by use of WHO DDDs, mostly because the WHO DDDs for 
penicillins, macrolides and aminoglycosides were set to low. Using pharmacy dispensing data 
from 1992 to 2003, de With et al evaluated antibiotic use in one large German university hospital 
by use of WHO DDDs and an alternate dose definition based on guideline recommendations. 86 
An overestimation of antibiotic use, as measured in WHO DDDs, was caused, for a large part, 
by too low set DDDs for amoxicillin-clavulanic acid. The authors also published a two-year 
survey of antibiotic use in 40 non-university hospitals from the same region, using both PDDs 
and WHO DDDs. 85 Finally, the same authors performed a prevalence survey at another German 
university hospital in 2006. They also determined PDDs from 471 antibiotic prescriptions in 971 
adult patients and, in addition, calculated recommended daily doses (RDDs) from local antibiotic 
guidelines. 86  They found that WHO DDDs overestimated antibiotic use by 36% when compared 
with PDDs, whereas RDDs, compared with PDDs, only led to a slight underestimation. Their 
conclusion, in accordance with our in Paper III, was that guideline-recommended dose 
definitions deviate from WHO DDDs, and the former is better suited better suited for the 
measurement of hospital antibiotic use.   





Few authors have focused on the WHO dose definition for antibiotic substances in the hospital 
environment. Previous publications have based their analyses on data from single institutions or 
hospitals belonging to a certain region, a fact that may question their external validity. Our study 
encompasses all Norwegian hospitals, which strengthens the generalizability of our findings. 
7.4. Factors decisive for hospital antibiotic use 
In Paper IV, we aimed to identify structural, geographical and clinical variables that may explain 
differences in hospital antibiotic use.  
A prerequisite for choosing the variables was that they should be easy to acquire and that they 
had been validated by official bodies (the Norwegian Patient Registry 153 and Statistics Norway 
154). Furthermore, the variables were selected with regard to both their clinical relevance and to 
their plausibility as explanatory factors for antibiotic use. 
Largely, the same factors independently predicted use of all antibiotics, broad-spectrum 
antibiotics and penicillins – this was the case for all four indices used in the regression models. 
We conclude that the explanatory factors identified are valid regardless of which dose unit that 
was applied but they had different impact, depending on the denominator.     
Few longitudinal studies have used aggregated antibiotic consumption data to investigate factors 
that determine antibiotic use in hospitals. Our study is the first to apply such analyses on a whole 
country. In a study of 74 southwestern French hospitals, antibiotic use and extent of antibiotic 
stewardship measures (ASM) were registered by use of questionnaires, and the relationship 
between ASM and trends for antibiotic use over five years were analysed. 155 A stable or 
decreasing use of ciprofloxacin and total antibiotics correlated with increased time used by a 
practice advisor and with a high frequency of antibiotic audits. The same authors published easily 
available adjustment criteria for 77 French hospitals’ antibiotic use in 2005 based on the same 
retrospective methodology. 156 They concluded that 84% of the variability in use between public 
hospitals could be explained by the proportion of patient days in the intensive care, surgical and 
medical wards.  
Prevalence surveys (see chapter 3.4.1, page 26) may be used to explore factors related to hospital 
antibiotic use. The advantage compared to longitudinal studies with aggregated data is that 
patient level information is available. Zarb and Amadeo, using ESAC point-prevalence studies 





from 2008 and 2009, 157 investigated antibiotic use in different age groups and found, not 
surprisingly, that extended use of antibiotics with a narrow therapeutic index (aminoglycosides 
and glycopeptides) represented a target for quality improvement in elderly patients. Two point-
prevalence surveys in France with 294 participating, non-teaching hospitals explored the use of 
antibiotics for hospital-acquired infections. 158 In this large study, low-level and high-level 
utilization hospitals were defined by below 25 and over 75 percentiles of total antibiotic use, 
respectively. Linear regression analysis showed that hospital size, high proportion of patients 
with immunodeficiency and patients with infection characteristics explained 45% of the variance 
in antibiotic use between hospitals. No regional (geographical) effect could be observed after 
adjusting for patient characteristics.  
Studies on the topic of hospital-acquired infections (HAIs) have been published in higher 
numbers than studies on antibiotic use. Because patients who are prescribed antibiotics usually 
have infections, studies of case-mix indices to adjust surveillance results for HAIs may be 
relevant also for antibiotic use. A Finnish nation-wide prevalence survey in 2005 aimed to 
establish a case-mix index to adjust inter-hospital differences in prevalence of HAIs. In a logistic 
regression analysis, urinary and central venous catheter use and a high McCabe and Jackson 
score 159,160 were the factors that significantly increased the odds for a presence of HAIs. The 
McCabe and Jackson score has been adapted for use in a recent European protocol dealing with 
prevalence surveys of antibiotic use in hospitals. Prevalence surveys of HAIs for case-mix 
adjustment has also been used to benchmark hospital’s infection rates in Cyprus and Greece. 118  
Clearly, it is desirable to stratify antibiotic utilization to comparable specialties in order to reduce 
the case-mix problems that arise when different hospitals are compared. An Israeli study of 26 
internal medicine departments used a multiple linear regression model to analyse factors that 
contributed to differences in antibiotic use. 161 Using a centralized hospital computer system, a 
series of variables were available for analysis. In addition to data on antibiotic use, variables 
related to hospital stay and patient-related variables were extracted. The latter included the 
Charlson co-morbidity index, 162 the rate of patients with neutropenia, pneumonia, urinary tract 
infections and cellulitis. They found that the rate of hospital stay lasting one day and hospital 
affiliation were the sole predictors of total antibiotic use, the former contributing only 7% and 
the latter 43% to the variance.  
In our study of explanatory factors in Paper IV, we were not able to include in the regression 
analyses stratification to single hospital units or a grouping of specialties. However, we could 





show that a non-university affiliation correlated with a higher use of all antibiotics, while a 
medium HE size and HE location in certain geographical regions correlated with higher use of 
broad-spectrum antibiotics.   
We conclude from Paper IV that after identifying explanatory factors that contributed to 
differences in hospitals’ antibiotic use, there remained an unexplained residual variance of 60%–
70% for broad-spectrum antibiotics and 30%–50% for all antibiotics. The factors we identified 
were mostly non-modifiable and we presume that the residual variations largely reflect 
prescriber-related factors. The identification of non-modifiable factors and the magnitude of their 
impact on variations in antibiotic use may help indicate areas where stewardship measures should 







8. General discussion 
8.1. Utilization of antibiotics in hospital – temporal trends 
During six years, from 2002 to 2007, the use of all antibiotics and in particular broad-spectrum 
antibiotics (BSAs) increased to an extent that could not be explained from the national antibiotic 
resistance situation at that time. A European study of antibiotic consumption in hospitals from 
the period 1997–2002 demonstrated that Scandinavian countries had lower total antibiotic use 
than other European countries. 64 In particular, they used less third-generation cephalosporins 
and penicillins with a β-lactamase-inhibitor. Consumption studies from other Scandinavian 
countries are of interest, since the neighbouring countries presumably have similar health care 
systems and prescribing habits. Jensen et al surveyed the use of antibiotics in Danish hospitals 
from 2001 to 2007 and found a 43% increase in total antibiotic use (44.7 to 69.4 DDDs/100 BDs) 
and a 180% increase in BSA use (9.4 to 26.3 DDDs/100BDs). 163 The proportion of BSAs related 
to all antibiotic use doubled, from 19.2% to 38.2%. These changes, from 2001 up until 2007, 
were more pronounced than the 18% increase in use of all antibiotics found in an earlier Danish 
study (1997–2001), which also demonstrated an increase in the proportion the broad-spectrum 
antibiotics constituted of all antibiotic use – but only from 16% to 19%.  
The Danish studies did not relate antibiotic use to the number of discharges. However, the 
authors did point out that the total number of patient bed days had successively decreased in 
Denmark, and that this lower number of bed days contributed by as much as 11% of the measured 
increase in hospital antibiotic use observed in the period 2001–2007. While the level of total 
antibiotic use, measured by DDDs/100 BDs, were almost identical in Denmark and Norway for 
the period 2001–2007, BSA use was almost twice as high in Denmark in 2007 as it was in 
Norway (26.3 versus 15.7 DDDs/100 BDs). The scale of the relative increase, both for all 
antibiotics and for BSAs, were also significantly higher in Denmark. In fact, the corresponding 
increases for Norway, 24.4% and 55.2% respectively, were more similar to the figures presented 
in the earlier Danish study (for the years 1997 to 2001). 
An Italian 3-year survey of five hospitals (2002-2004) 164 illustrates the disparity of the antibiotic 
profile between southern and northern European countries. In this study, BSAs constituted two 






betalactamase-inhibitor, which amounted to almost one third of the total use. By comparison, in 
Norway the use of agents belonging to this antibiotic class has been negligible. Moreover, the 
Italian hospitals’ use of fluoroquinolones and third-generation cephalosporins was three to four 
times higher than our figures from 2004.  
In a large survey of 530 hospitals from the south of France, it was found that in 2007 BSAs 
accounted for 25% of the total antibiotic use of 37.6 DDDs/100 patient days. 165 When including 
penicillins with enzyme-inhibitors in the BSA group, as we did in our studies, the proportion of 
BSAs was 59%. The French hospitals’ use of betalactamase-susceptible and -resistant penicillin 
was 0.15 DDDs/100 BDs and 1.0 DDDs/100 BDs, respectively, i.e. narrow-spectrum penicillins 
constituted 3.1% of the total use.  
Along the European north/south-axis, there is a striking difference in pattern of antibiotic use. 
The HEs from eastern Norway (Paper II, the period 2002–2007) used 19.9 DDDs/100 BDs 
(30.2%) of narrow-spectrum penicillins but only 16.8 DDDs/100 BDs (25.5%) of BSAs. A 
significant difference in total antibiotic use is also evident. The Norwegian hospitals’ total use, 
65.8 DDDs/100BDs, is higher than the French use by a factor of 1.75. This may in part have 
methodological explanations because 1) in the French study, psychiatric and rehabilitation wards 
with low antibiotic usage were included, and 2) the WHO DDDs for the narrow-spectrum 
penicillins are set lower than the doses actually used in hospital patients, a fact that inflates the 
number of doses registered for these substances.  
Consumption data derived from the Norwegian pharmacy database, partially reported in Paper 
III, give interesting information on temporal trends for the period 2006– 2011. For Norway, the 
increase in all HEs’ total antibiotic use (DDDs/100 BDs) from 2006 to 2011 was almost of the 
same size as the one noted for the eight HEs of Health Region East from 2002 to 2007 (16.5% 
and 17.4%, respectively). Of note, though, is the increase in use of BSAs, which was 
considerably lower in the latest national figures than in the first observation period in Health 
Region East (21% versus 50%).  
Since the two databases are different with regard to their hospital patient populations, 
unequivocal conclusions cannot be drawn by comparing the two periods. However, for the two 
years that the study databases overlap, 2006 and 2007, the total antibiotic use – measured for all 
HEs and including paediatric patients – was practically identical (regional data 62.7 and 65.1 






respective rates for 2006 and 2007 were 14.2 and 15.7 versus 15.4 and 16.5 DDDs/100 BDs. 
Altogether, this lends some support to the view that the use of resistance-driving antibiotics 
continues to increase, but at a lower grade in the recent years compared with the larger increase 
observed from 2002 to 2007.  
Using Drug Utilization (DU) 90% ranking, we found that all 22 Norwegian HEs had narrow-
spectrum penicillins as the number one used drugs when WHO DDDs were applied, whereas 
this was the case for only eight HEs when measured with haDDDs. Metronidazole, the 
cephalosporins and ciprofloxacin advanced in ranks while the penicillins received lower ranking 
with the haDDD measurements. Since narrow-spectrum penicillins are part of the Norwegian 
standard antibiotic regime for empiric treatment of community-acquired sepsis and pneumonia, 
an overall high ranking for these drugs is to be expected. The higher ranking of metronidazole is 
also plausible because it is the most used antibiotic for anaerobic infections. Furthermore, 
metronidazole is the first choice drug in gastrointestinal surgical prophylaxis, in combination 
with doxycycline. The advancement in ranking for first generation cephalosporins, mainly 
cefalotin, is probably also because of its extensive use in infection prophylaxis as a first choice 
antibiotic for almost all types of surgical procedures. Because of a short half-life of cefalotin, 
prophylaxis doses are often repeated two or three times during lengthy operations. In view of the 
high number of surgical procedures being performed, cefalotin prophylaxis generates a 
substantial number of doses that may most correctly measured by use of haDDDs. 
8.2. Antibiotic use in relation to resistance 
A high utilization of broad-spectrum antibiotics is documented beyond doubt to be the main 
driver of antibiotic resistance. Numerous studies have proved the role of increased antibiotic use 
for resistance development. This evidence has been inferred after use of various analytical 
methods and for a variety of “drug-bug” combinations, both in the hospital setting and in the 
community. 2,143,145,166-168 However, as is evident from several of these studies, antibiotic 
resistance appears after a variable time lag following an increase in antibiotic use. Furthermore, 
the picture is often complicated by lack of a clear relationship between the usage of a specific 






We documented a doubling of BSA use measured in DDDs/100BDs, and a 20% increase when 
measured as DDDs/100 discharges, in eight Norwegian HEs in the period 2002–2007. However, 
no antibiotic resistance existed that could explain the increase in BSA use, neither were difficult-
to-treat infections in hospitals observed in larger numbers – at least not at the national level. In 
2007, the MRSA rate among Staphylococcus aureus was << 1% of isolates (as it still is in 2013). 
The rates of extended-spectrum betalactamase (ESBL)-producing Enterobacteriaceae were still 
~1% and ciprofloxacin-resistance in Escherichia coli was 2.2%. In general, the percentage of 
major pathogens that were non-susceptible to most registered BSAs was very low. For 
community-acquired, severe systemic infections, more than 95% were adequately treated with a 
regimen of benzylpenicillin plus an aminoglycoside, with the addition of metronidazole if an 
abdominal focus was suspected. The mismatch observed between a rise in antibiotic 
consumption and concomitant low resistance levels supports the notion, unfortunately, that 
future increases in antibiotic resistance will be partly due to a current misuse of antibiotics. 
All countries in the world with the exception of Scandinavia and the Netherlands, experience an 
ongoing crisis of antibiotic resistance.169 The presently favourable situation in the Norwegian 
health care system is destined to change, and most probably to the worse. There are current trends 
to indicate that we are now commencing a progressive upward slope of an exponential antibiotic 
resistance curve. At the initiation of our studies presented in the Papers III and IV, covering the 
period 2006–2011, there were negligible problems in Norway with regard to resistance. Since 
then, a rise in the prevalence of multiresistant bacteria (e.g. ESBL-producing 
Enterobacteriaceae, carbapenase-producing Klebsiella and vancomycin-resistant enterococci) 
has been reported internationally. The proportions of ESBL-producing Escherichia coli and 
Klebsiella in blood cultures and urine samples have also increased at an alarming pace, although 
the rates are still low in Norway. In this situation, it is important to prevent a misuse of 
carbapenems since this antibiotic class is the last resort for the treatment of infections with 
ESBL-producing organisms. Carbapenem use increased in Norwegian HEs from 1.4 to 1.8 
DDDs/100BDs between 2006 and 2011 (34%). The increase for this antibiotic class may be even 
higher in intensive wards and certain medical and surgical specialties, in accordance with what 
we have shown for the “core units” in the previous period (2002–2007). These hospital units 
should be targets for further scrutiny and subjected to educational efforts and, preferably, even 






Of similar concern is the recent surge of gentamicin-resistance and a marked increase in 
ciprofloxacin-resistance in E. coli over the last 5–6 years. The increased resistance rates observed 
may not be explained by an increase in aminoglycoside use alone (from 2.1 to 2.7 DDDs/100BDs 
between 2006 and 2011). However, since aminoglycoside resistance is often transferred on 
mobile genetic elements, a co-selection of resistance may have occurred through the extended 
use of fluoroquinolones and third-generation cephalosporins, 170 increases that were documented 
in our studies throughout the period 2002–2011. Aminoglycosides are the backbones in many 
empiric combination treatments in Norway, which means that we until now have avoided the use 
of more resistance-driving broad-spectrum agents as a first choice. 171-174  
We found a significantly lower increase in the use of BSAs when analysing the national data 
(2006–2011) than for the Health Region East (2002–2007), which may well reflect a real 
difference between the national and regional utilization pattern. However, as discussed in chapter 
8.1 we believe that the recent lower trend observed for the BSA increase is real. One explanation 
could be that the Norwegian resistance development may have alerted clinicians to reduce their 
BSA use. It seems to be a paradox, then, to observe a reduced use of BSAs if increased numbers 
of resistant microorganisms are indeed causing infections in our hospitals. However, this 
strengthens a belief that antibiotic prescribing is guided less by bacteriological findings than by 
other factors, not all of them rational, but some of them with the potential to be influenced in a 
positive way. 175 
8.3. Strengths and limitations 
A common strength of our studies is the uniformity with which data on antibiotic use have been 
collected. We used a common source with pre-calculated DDDs and with detailed information 
about the hospital units that received the drugs. Because we did not rely on voluntary hospital 
participation by requesting them to supply study data, participation bias was not a problem. 
Furthermore, we used official sources for administrative data, thus providing precise counts, for 
example for patients’ bed days. In this way, the often used but less accurate, indirect calculations 
of these parameters by means of occupancy rates and number of ward beds could be avoided. 






requested from hospitals, e.g. by means of questionnaires, are entirely avoided by our 
methodology. 155 
Moreover, the results reported in the Papers III and IV are arrived at after analyses of a complete, 
national dataset. The database includes all Norwegian HEs and represent census data, not a 
population sample. Thus, no selection bias exists that could distort the applicability of the study 
results. This obviates the need for inferential statistics and adds to the strength of our conclusions.  
There are also some limitations of the studies. First, the centralization of medical services to 
fewer hospital units – mostly for fiscal reasons – represents a methodical challenge for hospital 
benchmarking of antibiotic use. Obviously, because data on antibiotic use should be evaluated 
locally, antibiotic surveillance results should preferably be reported for geographically separate 
hospitals and their specialties, rather than for whole Health Enterprises.  
In Paper II, data were acquired from each hospital pharmacy and administrative unit of the eight 
Health Enterprises. This enabled us to calculate antibiotic use densities for single hospital units 
and for medical specialties. However, the nationwide data for the Papers III and IV were 
extracted from a national database where administrative information was restricted to whole 
HEs. While this limitation was not important for our adjustment of WHO DDDs to haDDDs, in 
our exploration of explanatory factors the lack of an independent variable for the distribution of 
antibiotic use in medical specialties was disadvantageous. However, this limitation was not 
regarded a major drawback since one explicit purpose was to evaluate the existing data sources, 
and with a long-term objective of a possible role in a future national surveillance system.  
An inherent limitation of aggregated pharmacy sales data, used throughout this thesis, is the lack 
of information about the number of patients prescribed antibiotics and, furthermore, the 
unavailability of indications for use and duration of the antibiotic courses. Such information on 
the individual patient level represents is important in the evaluation of appropriate antibiotic 
prescribing. A most pertinent issue concerning data on antibiotic use data is feedback to local 
health care workers and administrators who are considered the most capable persons in the 







From this thesis, knowledge has been obtained about hospital antibiotic utilization in Norway.  
Up until now most of this information has not been present. We found a significant increase by 
almost 50% in the use of broad-spectrum antibiotics (BSAs) from 2002 to 2007 for all specialties 
and about 60% for “core units” (i.e. internal medicine, surgery and intensive care specialties). 
Corresponding increases related to hospital discharges were 20% and 30%. We observed that the 
increase in BSA use may have been abating in recent years. Still, the extent of BSA use in our 
hospitals is a concern because levels of antibiotic resistance in Norway are still low. Misuse will 
facilitate and open for a further resistance development.   
Although pharmacy sales data still represent aggregated measures of antibiotic use, the figures 
identified in this way are closer to the point of patient care than data from wholesalers. We have 
shown how caution must be exercised when the surveillance of hospitals’ short-term BSA use is 
based on pharmacy sales data. Another aspect of this thesis is the evaluation of antibiotic dose 
measurements in hospitals. We addressed the discrepancy between WHO assigned defined daily 
doses and the daily doses actually administered to hospital patients. With regard to some 
antibiotics, notably penicillins, the dose discrepancies are so pronounced that the surveillance 
results will become skewed.  
Moreover, a main conclusion is that both the number of bed days and the number of discharges 
should be used as denominators in antibiotic surveillance indices.  This is because the length of 
the patients’ hospital stays has declined steadily over time. Finally, our identification of 
explanatory factors that determine hospital antibiotic use are important in both a national and an 
international context.  
Today’s Norwegian health system, with large administrative unites organised as Health 
Enterprises, implies some limitations when national surveillance data are applied on the level of 
single institutions. On a general national level, our findings of antibiotic dose adjustments and 
explanatory factors will be useful for benchmarking of antibiotic use in the Health Enterprises.    
  
  





10. Implications and future research 
This thesis was conducted with a practical purpose in mind, namely that the methods we 
evaluated might facilitate the introduction of a future national surveillance system of hospital 
antibiotic use. Consequently, we described in detail both practical approaches for collecting and 
presenting surveillance data and the difficulties encountered. We propose efforts for overcoming 
some of the identified obstacles, for example easier access to the clinical and administrative data 
needed for optimal benchmarking of hospitals.  
The methodological issues addressed by this thesis have the following implications: 
1. Understanding the limitation of pharmacy sales data for short registration intervals 
(Paper I) is crucial both for evaluation of short-term surveillance results and 
intervention studies applying interrupted time-series design. 134,143,146 
2. The application of hospital-adjusted defined daily doses (haDDDs), described by us in 
Paper III, should be considered a supplement to the WHO DDDs in a future routine 
surveillance – possibly in combination with drug utilization (DU90%) ranking, which 
also has been evaluated by others. 133,152 
3. More resources should be allocated to the issue of adjusting antibiotic use in accordance 
with patient case-mix. Our study of explanatory factors for antibiotic use (Paper IV), 
applied on all Health Enterprises in Norway, revealed structural and geographical 
factors that explained antibiotic use dissimilarities, but there is a need for more research 
in this field.    
 
At an international level, Norway has participated in a surveillance network for hospital 
antibiotic use called European Surveillance of Antibiotic Consumption (ESAC) since its start as 
a project in 2001. 44 However, too few Norwegian institutions have contributed data to these 
surveys to make them representative of a national sample. The ESAC project is currently 
incorporated as ESAC-Net in the European Centre of Diseases Control (ECDC) surveillance 
network for nosocomial infections and antibiotic use. ESAC’s methods have largely been 
adopted and elaborated on, for example in a European protocol for point-prevalence surveillance 
of antibiotic use. 125  





More interaction with the ECDC and a higher degree of participation in European surveys should 
be encouraged by Norwegian health authorities. Such initiatives are in particular a responsibility 
of the National Institute of Public Health. National scientific projects, such as the studies 
presented in this thesis, may also serve as a basis for further protocols, for example for projects 
involving other Scandinavian countries. These countries have similarly structured health care 
systems, a fact that makes pharmacoepidemiological studies relatively easy to perform. 
Moreover, the low antibiotic resistance levels in Scandinavia provide unique opportunities for 
investigation of preventive measures that are not possible in “high-resistance countries”.  
Some future scientific questions and issues of interest: 
1. To develop more sophisticated and standardized methods for surveillance. 
i. To investigate new indices obtainable through routine surveillance that may 
be used to measure hospital antibiotic use. 
ii. Further evaluations of established methods of surveillance, and new 
approaches for their use – e.g. repeated prevalence surveys. 119,120,176-179 
iii. Investigations of the appropriateness of individual prescribing practices, 
monitored by various methods. 120,180-183 
2. To establish and evaluate determinants for antibiotic prescriptions, important in the 
work to change physician’s behaviour.  
i. Interviews and surveys of physicians’ prescription habits to investigate 
common behaviour determinants. 175,184 
ii. Investigate the rationale and strategies that underlie the process of writing and 
publishing guidelines. 185 
iii. Evaluate the following, in the search for effective stewardship measures: 
electronic decision aids, compulsory documentation of indications for 
antibiotic prescribing, 186 and automated stop orders for selected BSAs. 187,188 
3. To identify factors of importance for the development of antibiotic resistance in 
hospitals.  





i. Host- and bacteria-level studies to link individual antibiotic exposure to the 
emergence of resistance (typing, pathogenicity, pK/pD, etc). 189-193 
ii. Investigate risk factors for development of multiresistant bacterial strains 
104,167,193,194 and  factors which might reverse antibiotic resistance. 26,103,195,196  
 
This thesis has not addressed related issues, such as the optimal presentation of surveillance 
results at the hospital level, or the implementation of strategies to counteract antibiotic misuse. 
147 As a vehicle for activities in these fields, a “National competence centre for hospital antibiotic 
use” was established in Bergen (Helse Bergen - Haukeland University Hospital) in 2011. Also, 
the scientific community working for a prudent antibiotic prescribing has increased its activity 
in recent years. New national guidelines for antibiotic use in primary care has recently been 
revised 197 and new guidelines for antibiotic prescription in hospital patients have been 
developed. 198 More relevant PhD projects than ever are underway. Hopefully, these will throw 
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